Loeys-Dietz Syndrome

Mendelian MONDO:0018954 Pathograph 49 Show in embeddings browser Connective Tissue Disorders Marfan and Marfan-related Disorders

Loeys-Dietz syndrome (LDS) is an autosomal dominant connective tissue disorder caused by heterozygous mutations in genes encoding components of the TGF-beta signaling pathway, most commonly TGFBR1 and TGFBR2. It is characterized by the triad of arterial tortuosity and aneurysms, hypertelorism, and bifid uvula or cleft palate. Additional features include craniosynostosis, skeletal abnormalities (scoliosis, pectus deformity, joint laxity or contractures), thin translucent skin, and immunologic features (food allergy, eosinophilic gastrointestinal disease). LDS carries a high risk of aortic dissection at smaller aortic diameters than Marfan syndrome, with a mean age at death of 26.0 years in initial cohorts. Early diagnosis and aggressive surgical management are critical.

Ask OpenScientist

Ask a research question about Loeys-Dietz Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

2
Mappings
1
Definitions
2
Inheritance
5
Pathophys.
38
Phenotypes
49
Pathograph
8
Genes
3
Variants
4
Medical Actions
6
Subtypes
1
Differentials
2
Models
8
References
2
Deep Research
🏷

Classifications

ISDS Skeletal Nosology
overgrowth syndromes with skeletal involvement
🔗

Mappings

MONDO
MONDO:0012212 Loeys-Dietz syndrome 1 Not Yet Curated
skos:narrowMatch MONDO
TGFBR1-related Loeys-Dietz syndrome; covered by the Type 1 subtype of this umbrella entry, which is the sole dismech locus for this leaf class.
MONDO:0012427 Loeys-Dietz syndrome 2 Not Yet Curated
skos:narrowMatch MONDO
TGFBR2-related Loeys-Dietz syndrome; covered by the Type 2 subtype of this umbrella entry, which is the sole dismech locus for this leaf class.
📘

Definitions

1
Orphanet disease definition
Orphanet defines Loeys-Dietz syndrome as a rare genetic connective tissue disorder characterized by a broad spectrum of craniofacial, vascular and skeletal manifestations with four genetic subtypes described forming a clinical continuum.
CASE_DEFINITION
Show evidence (1 reference)
ORPHA:60030 SUPPORT Other
"Loeys-Dietz syndrome is a rare genetic connective tissue disorder characterized by a broad spectrum of craniofacial, vascular and skeletal manifestations with four genetic subtypes described forming a clinical continuum."
Orphanet's definition supports the multisystem connective-tissue framing of this entry.
👪

Inheritance

2
Autosomal Dominant
Autosomal dominant inheritance with variable expressivity.
Show evidence (2 references)
PMID:24577266 SUPPORT
"LDS, an autosomal-dominant connective tissue disorder first characterized by aortic aneurysms and generalized arterial tortuosity, hypertelorism, and bifid/broad uvula or cleft palate"
MacCarrick et al. confirm autosomal dominant inheritance in this comprehensive clinical management review.
ORPHA:60030 SUPPORT Other
"Autosomal dominant"
Orphanet records autosomal dominant inheritance for Loeys-Dietz syndrome.
Autosomal Recessive
Rare autosomal recessive inheritance has been reported for Loeys-Dietz syndrome, per Orphanet curation.
Show evidence (1 reference)
ORPHA:60030 SUPPORT Other
"Autosomal recessive"
Orphanet records autosomal recessive as an additional inheritance pattern for Loeys-Dietz syndrome.
◆

Subtypes

6
Loeys-Dietz Syndrome Type 1 (TGFBR1) MONDO:0012212
20-25% TGFBR1 hgnc:11772 HUGO Gene Nomenclature Committee (hgnc) Relation: this subtype is caused by variation in this gene This subtype is caused by variation in TGFBR1 (hgnc:11772). hgnc:11772 is a gene from the HUGO Gene Nomenclature Committee.
Caused by heterozygous mutations in TGFBR1, encoding the TGF-beta receptor type I kinase; most mutations cluster in the intracellular serine/threonine kinase domain and act through a mixture of haploinsufficiency and dominant-negative interference with the wild-type receptor rather than a single uniform mechanism. Often presents with more severe craniofacial features including craniosynostosis. Earlier cardiovascular surgery (mean age 16.9 years) and death (22.6 years) compared to type 2. Despite this, aortic specimens from TGFBR1-mutated individuals show a milder grade of cystic medial necrosis at histopathology than TGFBR2-mutated specimens, and a gene-based severity ranking places LDS1 among the more severe subtypes together with LDS2 (LDS1 = LDS2 > LDS3 > LDS4 > LDS5).
Show evidence (4 references)
PMID:40612107 SUPPORT Human Clinical
"a splice donor site variation in intron 5 (c.973 + 1 G>A) in a familial case of LDS was defined"
This review reports the clinical/genetic identification of a TGFBR1 splice-donor variant (c.973+1G>A) in a familial LDS case. This snippet establishes only that identification; the same source explicitly contrasts this specific variant against haploinsufficiency and instead anticipates a dominant-negative mechanism for it (see the COMPUTATIONAL evidence item immediately below).
PMID:40612107 SUPPORT Computational
"It is anticipated that this mutation will have a dominant-negative effect by causing the in-frame deletion of exon five within the STK domain"
The dominant-negative consequence of this splice-donor variant is described as "anticipated" -- a predicted structural effect of the in-frame exon-5 deletion on the kinase domain, not a directly measured receptor-interference result, so this is graded as an inferred/predicted claim rather than direct clinical or experimental evidence.
PMID:33408307 SUPPORT Human Clinical
"All patients with TGFBR2 mutations revealed grade III cystic medial necrosis (CMN), whereas 67% of patients with TGFBR1 mutations showed CMN (p = 0.033) and only one patient had grade III (p <0.001)."
Comparative histopathology of surgical aortic specimens shows that TGFBR1-mutated (LDS1) aortas have a milder grade of cystic medial necrosis than TGFBR2-mutated (LDS2) aortas, a histological distinction between the two most common LDS subtypes.
+ 1 more reference
Loeys-Dietz Syndrome Type 2 (TGFBR2) MONDO:0012427
55-60% TGFBR2 hgnc:11773 HUGO Gene Nomenclature Committee (hgnc) Relation: this subtype is caused by variation in this gene This subtype is caused by variation in TGFBR2 (hgnc:11773). hgnc:11773 is a gene from the HUGO Gene Nomenclature Committee.
Caused by heterozygous mutations in TGFBR2, encoding the TGF-beta receptor type II. Characterized kinase-domain variants impair canonical SMAD2/3 signaling and act through dominant-negative interference with the receptor complex rather than simple haploinsufficiency, which a Tgfbr2 knockin mouse corroborates in vivo. Aortic disease is severe: aortic specimens from TGFBR2-mutated individuals show uniformly higher-grade cystic medial necrosis than TGFBR1-mutated specimens, a paediatric TGFBR2 cohort showed larger aortic z-scores and stiffer, less distensible aortas at the annulus, sinotubular junction and ascending aorta than its TGFBR1 comparator, and the gene-based severity ranking places LDS2 alongside LDS1 as the most severe classes (LDS1 = LDS2 > LDS3 > LDS4 > LDS5). Female TGFBR2 carriers were a higher-risk group for aortic dissection after initial surgery in one surgical series. An allele-specific ocular association has been reported for TGFBR2 Arg528 missense variants, which in two cases produced a familial exudative vitreoretinopathy-like retinal phenotype; this is not established as a general LDS2 feature. Two older descriptive claims are retained from the original entry but must be read with their provenance: "more prominent cutaneous features and phenotypic overlap with vascular Ehlers-Danlos syndrome", and later cardiovascular surgery (mean age 26.9 years) and death (31.8 years) than type 1, both derive from Loeys et al. 2006's *clinically* defined type II cohort - selected for a vascular-Ehlers-Danlos-like, craniofacially spared presentation - and not from a TGFBR2-genotyped cohort. They should not be read as showing that TGFBR2 disease is milder or craniofacially spared: the paediatric genotyped comparison above found craniofacial features similar in the TGFBR1 and TGFBR2 groups. Nosology note: "type 2" has a modern gene-based sense (the TGFBR2 class of the LDS1-6 gene series, used here and by MONDO:0012427 / OMIM:610168) and an older gene-agnostic clinical sense from Loeys et al. 2006; see review_notes for why MONDO's free-text definition still names both receptor genes.
Show evidence (14 references)
PMID:16928994 SUPPORT Human Clinical
"We found a mutation in TGFBR1 or TGFBR2 in all probands with typical Loeys-Dietz syndrome (type I) and in 12 probands presenting with vascular Ehlers-Danlos syndrome (Loeys-Dietz syndrome type II)"
Sources the historical, purely clinical sense of "Loeys-Dietz syndrome type II" - a vascular-Ehlers-Danlos-like presentation - and shows it was gene-agnostic, with probands of both types carrying TGFBR1 or TGFBR2 mutations. This is the origin of the "either TGFBR1 or TGFBR2" wording in MONDO:0012427's imported free-text definition, recorded here so the historical clinical sense is not mistaken for the modern gene-based one this subtype is bound to.
PMID:16928994 SUPPORT Human Clinical
"Patients with Loeys-Dietz syndrome type I, as compared with those with type II, underwent cardiovascular surgery earlier (mean age, 16.9 years vs. 26.9 years) and died earlier (22.6 years vs. 31.8 years)"
Sources the mean age at cardiovascular surgery (26.9 years) and at death (31.8 years) quoted in this subtype description. These figures come from the clinically defined type II cohort quoted in the item above, not from a TGFBR2-genotyped cohort, which is why the description flags their provenance rather than presenting them as a TGFBR2 genotype effect.
PMID:33408307 SUPPORT Human Clinical
"All patients with TGFBR2 mutations revealed grade III cystic medial necrosis (CMN), whereas 67% of patients with TGFBR1 mutations showed CMN"
Comparative histopathology of surgical aortic specimens shows uniformly grade III cystic medial necrosis in TGFBR2-mutated (LDS2) aortas against a lower grade in TGFBR1-mutated specimens, supporting the more severe medial degeneration attributed to LDS2 here.
+ 11 more references
Loeys-Dietz Syndrome Type 3 (SMAD3) MONDO:0013426
SMAD3 hgnc:6769 HUGO Gene Nomenclature Committee (hgnc) Relation: this subtype is caused by variation in this gene This subtype is caused by variation in SMAD3 (hgnc:6769). hgnc:6769 is a gene from the HUGO Gene Nomenclature Committee.
Caused by mutations in SMAD3. Associated with early-onset osteoarthritis (aneurysms-osteoarthritis syndrome) and increased prevalence of mitral valve prolapse.
Loeys-Dietz Syndrome Type 4 (TGFB2) MONDO:0013897
TGFB2 hgnc:11768 HUGO Gene Nomenclature Committee (hgnc) Relation: this subtype is caused by variation in this gene This subtype is caused by variation in TGFB2 (hgnc:11768). hgnc:11768 is a gene from the HUGO Gene Nomenclature Committee.
Caused by heterozygous mutations in TGFB2. The vascular course is generally milder and later-onset than TGFBR1/TGFBR2-related disease (aneurysms typically apparent in the fourth decade), but articular and skeletal involvement is prevalent and can dominate the presentation even in the absence of any vascular event.
Show evidence (1 reference)
PMID:25163805 SUPPORT Human Clinical
"loss-of-function mutations in TGFB2 gene do not always lead to aggressive vascular phenotypes and that articular and skeletal signs are prevalent"
Corrects a prior version of this stub, which stated LDS4 has "lower prevalence of musculoskeletal involvement" - the transposed opposite of this paper's conclusion: articular/skeletal signs are prevalent and can be the only presenting feature, while it is the vascular phenotype that is comparatively mild.
Loeys-Dietz Syndrome Type 5 (TGFB3) MONDO:0014262
TGFB3 hgnc:11769 HUGO Gene Nomenclature Committee (hgnc) Relation: this subtype is caused by variation in this gene This subtype is caused by variation in TGFB3 (hgnc:11769). hgnc:11769 is a gene from the HUGO Gene Nomenclature Committee.
Caused by mutations in TGFB3. Milder phenotype with variable penetrance.
Loeys-Dietz Syndrome Type 6 (SMAD2) MONDO:0030500
SMAD2 hgnc:6768 HUGO Gene Nomenclature Committee (hgnc) Relation: this subtype is caused by variation in this gene This subtype is caused by variation in SMAD2 (hgnc:6768). hgnc:6768 is a gene from the HUGO Gene Nomenclature Committee.
Caused by heterozygous mutations in SMAD2, an intracellular TGF-beta signaling effector paralogous to SMAD3 (Type 3/AOS). Previously absent from this umbrella's has_subtypes list entirely.
⚙

Pathophysiology

5
Paradoxical TGF-beta Signaling
Loss-of-function mutations in TGF-beta receptors paradoxically lead to increased TGF-beta signaling in the aortic wall, mediated through non-canonical pathways and compensatory upregulation. This results in excessive SMAD2/3 phosphorylation and activation of ERK and p38 MAPK downstream targets that promote extracellular matrix degradation.
Vascular Smooth Muscle Cell CL:0000359 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Vascular Smooth Muscle Cell, annotated with vascular associated smooth muscle cell (CL:0000359). CL:0000359 is a cell type from the Cell Ontology. Fibroblast CL:0000057 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Fibroblast (CL:0000057). CL:0000057 is a cell type from the Cell Ontology.
TGF-beta Signaling GO:0007179 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased TGF-beta Signaling, annotated with transforming growth factor beta receptor signaling pathway (GO:0007179). GO:0007179 is a biological process from the Gene Ontology. ↑ INCREASED SMAD Signaling GO:0060395 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased SMAD Signaling, annotated with SMAD protein signal transduction (GO:0060395). GO:0060395 is a biological process from the Gene Ontology. ↑ INCREASED
Animal models
Tgfbr1 M318R/+ knock-in mouse (LDS Type 1) Mouse recapitulates A TGFBR1-specific (LDS type 1) knock-in mouse carrying the human M318R kinase-domain missense mutation recapitulates the LDS vascular phenotype, unlike simple Tgfbr1 haploinsufficiency, and reproduces the paradoxical in vivo increase in aortic-wall TGF-beta/SMAD2 signaling despite diminished receptor response to exogenous ligand in vitro.
Downstream
Extracellular Matrix Degradation Enhanced TGF-beta/SMAD signaling drives matrix metalloproteinase upregulation and degradation of the aortic wall extracellular matrix.
Show evidence (2 references)
PMID:21493862 SUPPORT Model Organism
"extracellular signal-regulated kinase (ERK) 1 and 2 and Smad2 are activated in a mouse model of MFS, and both are inhibited by therapies directed against TGFbeta"
Holm et al. demonstrate that both canonical (Smad2) and noncanonical (ERK1/2) TGF-beta signaling are activated in aortic disease, and selective ERK1/2 inhibition ameliorates aortic growth while Smad4 deficiency exacerbates disease.
PMID:16928994 SUPPORT Human Clinical
"The disease is characterized by the triad of arterial tortuosity and aneurysms, hypertelorism, and bifid uvula or cleft palate and is caused by heterozygous mutations in the genes encoding transforming growth factor beta receptors 1 and 2 (TGFBR1 and TGFBR2, respectively)"
The landmark Loeys et al. 2006 NEJM paper establishes TGF-beta receptor mutations as the cause and defines the clinical triad.
Noncanonical MAPK Pathway Activation
In addition to canonical SMAD signaling, noncanonical ERK1/2 and JNK pathways are prominently activated in LDS aortic tissue. Selective inhibition of ERK1/2 ameliorates aortic growth, while JNK antagonism is also protective. These non-SMAD pathways may be the primary drivers of aortic disease progression.
ERK Cascade GO:0070371 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves ERK Cascade, annotated with ERK1 and ERK2 cascade (GO:0070371). GO:0070371 is a biological process from the Gene Ontology. JNK Cascade GO:0007254 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves JNK Cascade (GO:0007254). GO:0007254 is a biological process from the Gene Ontology.
Show evidence (1 reference)
PMID:21493862 SUPPORT Model Organism
"noncanonical (Smad-independent) TGFbeta signaling is a prominent driver of aortic disease in MFS mice, and inhibition of the ERK1/2 or JNK1 pathways is a potential therapeutic strategy for the disease"
Holm et al. establish noncanonical TGF-beta signaling via ERK and JNK as key drivers of aortic aneurysm progression.
Extracellular Matrix Degradation
Enhanced TGF-beta signaling leads to upregulation of matrix metalloproteinases (MMPs) and reduced expression of tissue inhibitors, causing degradation of elastic fibers and collagen in the arterial wall. This weakens the vessel wall leading to aneurysm formation and dissection.
vascular associated smooth muscle cell CL:0000359 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves vascular associated smooth muscle cell (CL:0000359). CL:0000359 is a cell type from the Cell Ontology.
Extracellular Matrix Disassembly GO:0022617 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased Extracellular Matrix Disassembly (GO:0022617). GO:0022617 is a biological process from the Gene Ontology. ↑ INCREASED Elastic Fiber Assembly GO:0048251 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased Elastic Fiber Assembly (GO:0048251). GO:0048251 is a biological process from the Gene Ontology. ↓ DECREASED
Aorta UBERON:0000947 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in Aorta (UBERON:0000947). UBERON:0000947 is an anatomical location from the Uberon multi-species anatomy ontology.
Experimental models
hiPSC-derived bioengineered vascular graft, TGFBR1 A230T (LDS Type 1) IPSC DERIVED MODEL TGFBR1 A230T bioengineered vascular grafts show defective extracellular-matrix gene expression, decreased collagen hydroxylation, and impaired smooth-muscle-cell organization. This overlaps this node's elastic-fiber-assembly arm (GO:0048251 DECREASED) and its net aortic-wall-weakening consequence, but the graft's dominant mechanism is defective ECM SYNTHESIS/maturation (reduced collagen-modifying enzyme activity) rather than the MMP-driven ECM DISASSEMBLY (GO:0022617 INCREASED) this node principally asserts, so the model is graded a partial recapitulation rather than a full one.
Downstream
Aortic Aneurysm Degradation of elastic fibers and collagen weakens the aortic media, promoting aneurysmal dilation.
Aortic Dissection Progressive medial weakening predisposes to dissection, characteristically at smaller aortic diameters than in Marfan syndrome.
Aortic Root Aneurysm
Arterial Dissection
Arterial Tortuosity
Pregnancy-Related Vascular Complications
Patent Ductus Arteriosus
Uterine Rupture
Mitral Regurgitation
Spontaneous Pneumothorax
Translucent Skin
Striae Distensae
Atypical Scarring of Skin
Bruising Susceptibility
Show evidence (3 references)
PMID:18852674 SUPPORT Human Clinical
"LDS samples had increased medial collagen and a subtle but diffuse form of elastic fiber fragmentation and extracellular matrix deposition, referred to as diffuse medial degeneration."
Histopathology of ascending aortic root tissue from 15 LDS patients documents diffuse medial degeneration with elastic-fiber fragmentation, supporting the elastin-integrity loss and wall weakening this node asserts. Graded PARTIAL because the same study reports *increased* medial collagen and extracellular-matrix *deposition* (fibrosis), not net collagen loss — so it supports the elastic-fiber-degradation arm but not a collagen-degradation reading of this node.
PMID:18852674 SUPPORT Human Clinical
"an immunohistochemical stain for pSmad2, a marker of TGFbeta activity, was significantly increased in LDS patients compared with controls"
Increased pSmad2 in LDS aortic tissue confirms the enhanced TGF-beta signaling that this node identifies as the upstream driver of the medial ECM remodeling.
PMID:36606286 SUPPORT Human Clinical
"All groups of HTAD patients had increased levels matrix metalloproteinase-9 (MMP-9) as compared with healthy controls, also in adjusted analyses, reflecting altered ECM remodeling."
A heritable-thoracic-aortic-disease cohort including 12 Loeys-Dietz patients shows increased circulating MMP-9 versus controls, directly evidencing the matrix-metalloproteinase upregulation this node asserts; the authors conclude "upregulated MMP-9, a matrix degrading enzyme, is a common feature of several subgroups of HTAD."
Skeletal Development Disruption
TGF-beta signaling is critical for skeletal development, particularly in suture closure and vertebral column formation. Dysregulated signaling leads to craniosynostosis, scoliosis, and cervical spine instability. Cervical spine findings are prominent in LDS 1/2 (51% of patients).
Skeletal System Development GO:0001501 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves Skeletal System Development (GO:0001501). GO:0001501 is a biological process from the Gene Ontology. Cranial Suture Morphogenesis GO:0060363 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves Cranial Suture Morphogenesis (GO:0060363). GO:0060363 is a biological process from the Gene Ontology.
Downstream
Hypertelorism
Bifid Uvula
Cleft Palate
Craniosynostosis
Scoliosis
Pectus Excavatum
Joint Hypermobility
Cervical Spine Instability
Clubfoot
Osteoporosis
Early-Onset Osteoarthritis
Tall Stature
Malar Flattening
Micrognathia
Blue Sclerae
Arachnodactyly
Camptodactyly
Pes Planus
Joint Dislocation
Myopia
Show evidence (1 reference)
PMID:24577266 SUPPORT Human Clinical
"Cervical spine findings are prominent features in LDS 1/2 (51%), but presence in LDS 3 and 4 is unknown"
MacCarrick et al. document cervical spine abnormalities in over half of LDS type 1/2 patients.
Immune Dysregulation
LDS is associated with a high prevalence of immunologic features including food allergy (31%), eosinophilic gastrointestinal disease, asthma, eczema, and allergic rhinitis. TGF-beta pathway disruption affects immune regulation and mucosal tolerance.
Immune Response Regulation GO:0050776 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves Immune Response Regulation, annotated with regulation of immune response (GO:0050776). GO:0050776 is a biological process from the Gene Ontology.
Downstream
Food Allergy
Asthma
Eczematoid Dermatitis
Eosinophilic Esophageal Infiltration
Show evidence (1 reference)
PMID:24577266 SUPPORT Human Clinical
"LDS has been associated with a high prevalence of immunologic features including asthma, food allergy, eczema, and allergic rhinitis"
MacCarrick et al. document significant immune dysregulation in LDS, with food allergy prevalence of 31% compared to 6-8% in the general population.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Loeys-Dietz Syndrome Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

38
Blood 1
Bruising Susceptibility OCCASIONAL HP:0000978 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Bruising susceptibility (HP:0000978). HP:0000978 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:60030 SUPPORT Other
"HP:0000978 | Bruising susceptibility | Occasional (29-5%)"
Orphanet's curated HPO frequency annotation classifies bruising susceptibility as Occasional (29-5%) in Loeys-Dietz syndrome.
Cardiovascular 5
Aortic Aneurysm VERY_FREQUENT HP:0004942 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Aortic aneurysm (HP:0004942). HP:0004942 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:16928994 SUPPORT Human Clinical
"The natural history of both types was characterized by aggressive arterial aneurysms (mean age at death, 26.0 years) and a high incidence of pregnancy-related complications (in 6 of 12 women)"
Loeys et al. document aggressive aneurysmal disease with early mortality in 52 families with LDS.
ORPHA:60030 SUPPORT Other
"HP:0004942 | Aortic aneurysm | Very frequent (99-80%)"
Orphanet's curated HPO frequency annotation classifies aortic aneurysm as Very frequent (99-80%) in Loeys-Dietz syndrome.
Aortic Root Aneurysm HP:0002616 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Aortic root aneurysm (HP:0002616). HP:0002616 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:24577266 SUPPORT Human Clinical
"dissections have occurred in individuals with LDS 1, 2, or 3 at aortic dimensions of 3.9-4.0 cm"
MacCarrick et al. note dissections at smaller diameters than Marfan syndrome, supporting more aggressive surgical thresholds.
Aortic Dissection VERY_FREQUENT HP:0002647 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Aortic dissection (HP:0002647). HP:0002647 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:16928994 SUPPORT Human Clinical
"The natural history of both types was characterized by aggressive arterial aneurysms (mean age at death, 26.0 years) and a high incidence of pregnancy-related complications (in 6 of 12 women)"
Loeys et al. document aggressive aneurysmal disease leading to dissection and early mortality.
ORPHA:60030 SUPPORT Other
"HP:0002647 | Aortic dissection | Very frequent (99-80%)"
Orphanet's curated HPO frequency annotation classifies aortic dissection as Very frequent (99-80%) in Loeys-Dietz syndrome.
Arterial Tortuosity VERY_FREQUENT HP:0005116 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Arterial tortuosity (HP:0005116). HP:0005116 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:35662564 SUPPORT Human Clinical
"the most commonly reported features and complications being: aortic aneurysms and dissections, arterial tortuosity, high arched palate, abnormal uvula and hypertelorism"
Systematic review of 3896 LDS cases confirms arterial tortuosity as one of the most common features.
ORPHA:60030 SUPPORT Other
"HP:0005116 | Arterial tortuosity | Very frequent (99-80%)"
Orphanet's curated HPO frequency annotation classifies arterial tortuosity as Very frequent (99-80%) in Loeys-Dietz syndrome.
Patent Ductus Arteriosus VERY_FREQUENT HP:0001643 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Patent ductus arteriosus (HP:0001643). HP:0001643 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:60030 SUPPORT Other
"HP:0001643 | Patent ductus arteriosus | Very frequent (99-80%)"
Orphanet's curated HPO frequency annotation classifies patent ductus arteriosus as Very frequent (99-80%) in Loeys-Dietz syndrome.
Eye 3
Hypertelorism FREQUENT HP:0000316 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypertelorism (HP:0000316). HP:0000316 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:16928994 SUPPORT Human Clinical
"The disease is characterized by the triad of arterial tortuosity and aneurysms, hypertelorism, and bifid uvula or cleft palate"
Hypertelorism is part of the defining diagnostic triad.
ORPHA:60030 SUPPORT Other
"HP:0000316 | Hypertelorism | Frequent (79-30%)"
Orphanet's curated HPO frequency annotation classifies hypertelorism as Frequent (79-30%) in Loeys-Dietz syndrome.
Blue Sclerae FREQUENT HP:0000592 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Blue sclerae (HP:0000592). HP:0000592 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:60030 SUPPORT Other
"HP:0000592 | Blue sclerae | Frequent (79-30%)"
Orphanet's curated HPO frequency annotation classifies blue sclerae as Frequent (79-30%) in Loeys-Dietz syndrome.
Myopia OCCASIONAL HP:0000545 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Myopia (HP:0000545). HP:0000545 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:60030 SUPPORT Other
"HP:0000545 | Myopia | Occasional (29-5%)"
Orphanet's curated HPO frequency annotation classifies myopia as Occasional (29-5%) in Loeys-Dietz syndrome.
Head and Neck 5
Bifid Uvula FREQUENT HP:0000193 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Bifid uvula (HP:0000193). HP:0000193 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:16928994 SUPPORT Human Clinical
"The disease is characterized by the triad of arterial tortuosity and aneurysms, hypertelorism, and bifid uvula or cleft palate"
Bifid uvula is part of the defining diagnostic triad.
ORPHA:60030 SUPPORT Other
"HP:0000193 | Bifid uvula | Frequent (79-30%)"
Orphanet's curated HPO frequency annotation classifies bifid uvula as Frequent (79-30%) in Loeys-Dietz syndrome.
Cleft Palate FREQUENT HP:0000175 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cleft palate (HP:0000175). HP:0000175 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:60030 SUPPORT Other
"HP:0000175 | Cleft palate | Frequent (79-30%)"
Orphanet's curated HPO frequency annotation classifies cleft palate as Frequent (79-30%) in Loeys-Dietz syndrome.
Craniosynostosis FREQUENT HP:0001363 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Craniosynostosis (HP:0001363). HP:0001363 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:24577266 SUPPORT Human Clinical
"Most commonly, the sagittal suture is prematurely closed, but the coronal, metopic, and squamosal sutures can also be involved"
MacCarrick et al. describe the pattern of suture involvement in LDS craniosynostosis.
ORPHA:60030 SUPPORT Other
"HP:0001363 | Craniosynostosis | Frequent (79-30%)"
Orphanet's curated HPO frequency annotation classifies craniosynostosis as Frequent (79-30%) in Loeys-Dietz syndrome.
Malar Flattening FREQUENT HP:0000272 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Malar flattening (HP:0000272). HP:0000272 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:60030 SUPPORT Other
"HP:0000272 | Malar flattening | Frequent (79-30%)"
Orphanet's curated HPO frequency annotation classifies malar flattening as Frequent (79-30%) in Loeys-Dietz syndrome.
Micrognathia FREQUENT HP:0000347 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Micrognathia (HP:0000347). HP:0000347 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:60030 SUPPORT Other
"HP:0000347 | Micrognathia | Frequent (79-30%)"
Orphanet's curated HPO frequency annotation classifies micrognathia as Frequent (79-30%) in Loeys-Dietz syndrome.
Immune 2
Food Allergy HP:0500093 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Food allergy (HP:0500093). HP:0500093 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:24577266 SUPPORT Human Clinical
"A conservative prevalence estimate of food allergies in this population is 31% (compared with 6-8% prevalence in the general population)"
Food allergy prevalence is approximately 4-5 times higher in LDS than in the general population.
Eczematoid Dermatitis FREQUENT HP:0000964 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Eczematoid dermatitis (HP:0000964). HP:0000964 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:60030 SUPPORT Other
"HP:0000964 | Eczematoid dermatitis | Frequent (79-30%)"
Orphanet's curated HPO frequency annotation classifies eczematoid dermatitis as Frequent (79-30%) in Loeys-Dietz syndrome.
Integument 3
Translucent Skin Dermal translucency HP:0010648 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Translucent skin, annotated with Dermal translucency (HP:0010648). HP:0010648 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:24577266 SUPPORT Human Clinical
"Cutaneous findings in LDS include velvety, thin, translucent skin with easy bruising and visible veins"
MacCarrick et al. describe the cutaneous features of LDS.
Striae Distensae FREQUENT HP:0001065 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Striae distensae (HP:0001065). HP:0001065 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:60030 SUPPORT Other
"HP:0001065 | Striae distensae | Frequent (79-30%)"
Orphanet's curated HPO frequency annotation classifies striae distensae as Frequent (79-30%) in Loeys-Dietz syndrome.
Atypical Scarring of Skin FREQUENT HP:0000987 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Atypical scarring of skin (HP:0000987). HP:0000987 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:60030 SUPPORT Other
"HP:0000987 | Atypical scarring of skin | Frequent (79-30%)"
Orphanet's curated HPO frequency annotation classifies atypical scarring of skin as Frequent (79-30%) in Loeys-Dietz syndrome.
Limbs 3
Clubfoot FREQUENT Talipes equinovarus HP:0001762 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Clubfoot, annotated with Talipes equinovarus (HP:0001762). HP:0001762 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:60030 SUPPORT Other
"HP:0001762 | Talipes equinovarus | Frequent (79-30%)"
Orphanet's curated HPO frequency annotation classifies talipes equinovarus as Frequent (79-30%) in Loeys-Dietz syndrome.
Arachnodactyly FREQUENT HP:0001166 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Arachnodactyly (HP:0001166). HP:0001166 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:60030 SUPPORT Other
"HP:0001166 | Arachnodactyly | Frequent (79-30%)"
Orphanet's curated HPO frequency annotation classifies arachnodactyly as Frequent (79-30%) in Loeys-Dietz syndrome.
Pes Planus VERY_FREQUENT HP:0001763 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Pes planus (HP:0001763). HP:0001763 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:24577266 SUPPORT Human Clinical
"Skeletal features in all types of LDS can show overlap with Marfan syndrome, including pectus deformity, scoliosis, and flat feet"
MacCarrick et al. confirm flat feet across all LDS types.
ORPHA:60030 SUPPORT Other
"HP:0001763 | Pes planus | Very frequent (99-80%)"
Orphanet's curated HPO frequency annotation classifies pes planus as Very frequent (99-80%) in Loeys-Dietz syndrome.
Musculoskeletal 7
Scoliosis FREQUENT HP:0002650 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Scoliosis (HP:0002650). HP:0002650 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:60030 SUPPORT Other
"HP:0002650 | Scoliosis | Frequent (79-30%)"
Orphanet's curated HPO frequency annotation classifies scoliosis as Frequent (79-30%) in Loeys-Dietz syndrome.
Pectus Excavatum OCCASIONAL HP:0000767 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Pectus excavatum (HP:0000767). HP:0000767 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:24577266 SUPPORT Human Clinical
"Skeletal features in all types of LDS can show overlap with Marfan syndrome, including pectus deformity, scoliosis, and flat feet"
Pectus deformity confirmed across all LDS types in clinical review.
ORPHA:60030 SUPPORT Other
"HP:0000767 | Pectus excavatum | Occasional (29-5%)"
Orphanet's curated HPO frequency annotation classifies pectus excavatum as Occasional (29-5%) in Loeys-Dietz syndrome.
Joint Hypermobility FREQUENT HP:0001382 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Joint hypermobility (HP:0001382). HP:0001382 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:24577266 SUPPORT Human Clinical
"Extremity contractures in conjunction with joint hyperextension are unusual in the general population but common in LDS"
The coexistence of contractures and hypermobility is a distinctive feature of LDS.
ORPHA:60030 SUPPORT Other
"HP:0001382 | Joint hypermobility | Frequent (79-30%)"
Orphanet's curated HPO frequency annotation classifies joint hypermobility as Frequent (79-30%) in Loeys-Dietz syndrome.
Cervical Spine Instability HP:0010646 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cervical spine instability (HP:0010646). HP:0010646 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:24577266 SUPPORT Human Clinical
"Cervical spine findings are prominent features in LDS 1/2 (51%)"
Over half of LDS type 1/2 patients have cervical spine abnormalities.
Osteoporosis HP:0000939 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Osteoporosis (HP:0000939). HP:0000939 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:24577266 SUPPORT Human Clinical
"at least 60% of patients had low or very low bone mineral density in the spine, hip, and/or femoral neck"
High fracture risk and low BMD documented in LDS patients.
Early-Onset Osteoarthritis HP:0002758 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Osteoarthritis (HP:0002758). HP:0002758 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:21217753 SUPPORT Human Clinical
"In contrast with other aneurysm syndromes, most of these affected individuals presented with early-onset osteoarthritis"
van de Laar et al. identified SMAD3 mutations as cause of aneurysms-osteoarthritis syndrome.
PMID:35662564 SUPPORT Human Clinical
"LDS Type 3 demonstrated an increased prevalence of mitral valve prolapse and arthritis"
Systematic review confirms LDS type 3 association with arthritis.
Joint Dislocation OCCASIONAL HP:0001373 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Joint dislocation (HP:0001373). HP:0001373 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:60030 SUPPORT Other
"HP:0001373 | Joint dislocation | Occasional (29-5%)"
Orphanet's curated HPO frequency annotation classifies joint dislocation as Occasional (29-5%) in Loeys-Dietz syndrome.
Prenatal and Birth 1
Growth 1
Tall Stature FREQUENT HP:0000098 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Tall stature (HP:0000098). HP:0000098 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:60030 SUPPORT Other
"HP:0000098 | Tall stature | Frequent (79-30%)"
Orphanet's curated HPO frequency annotation classifies tall stature as Frequent (79-30%) in Loeys-Dietz syndrome.
Other 7
Arterial Dissection VERY_FREQUENT HP:0005294 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Arterial dissection (HP:0005294). HP:0005294 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:60030 SUPPORT Other
"HP:0005294 | Arterial dissection | Very frequent (99-80%)"
Orphanet's curated HPO frequency annotation classifies arterial dissection as Very frequent (99-80%) in Loeys-Dietz syndrome.
Camptodactyly FREQUENT Camptodactyly of finger HP:0100490 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Camptodactyly of finger (HP:0100490). HP:0100490 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:60030 SUPPORT Other
"HP:0100490 | Camptodactyly of finger | Frequent (79-30%)"
Orphanet's curated HPO frequency annotation classifies camptodactyly of finger as Frequent (79-30%) in Loeys-Dietz syndrome.
Uterine Rupture VERY_FREQUENT HP:0100718 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Uterine rupture (HP:0100718). HP:0100718 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:60030 SUPPORT Other
"HP:0100718 | Uterine rupture | Very frequent (99-80%)"
Orphanet's curated HPO frequency annotation classifies uterine rupture as Very frequent (99-80%) in Loeys-Dietz syndrome.
Asthma FREQUENT HP:0002099 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Asthma (HP:0002099). HP:0002099 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:24577266 SUPPORT Human Clinical
"LDS has been associated with a high prevalence of immunologic features including asthma, food allergy, eczema, and allergic rhinitis"
MacCarrick et al. document asthma as part of the immunologic phenotype.
ORPHA:60030 SUPPORT Other
"HP:0002099 | Asthma | Frequent (79-30%)"
Orphanet's curated HPO frequency annotation classifies asthma as Frequent (79-30%) in Loeys-Dietz syndrome.
Mitral Regurgitation OCCASIONAL HP:0001653 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Mitral regurgitation (HP:0001653). HP:0001653 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:60030 SUPPORT Other
"HP:0001653 | Mitral regurgitation | Occasional (29-5%)"
Orphanet's curated HPO frequency annotation classifies mitral regurgitation as Occasional (29-5%) in Loeys-Dietz syndrome.
Spontaneous Pneumothorax OCCASIONAL HP:0002108 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Spontaneous pneumothorax (HP:0002108). HP:0002108 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:60030 SUPPORT Other
"HP:0002108 | Spontaneous pneumothorax | Occasional (29-5%)"
Orphanet's curated HPO frequency annotation classifies spontaneous pneumothorax as Occasional (29-5%) in Loeys-Dietz syndrome.
Eosinophilic Esophageal Infiltration OCCASIONAL Eosinophilic infiltration of the esophagus HP:0410151 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Eosinophilic infiltration of the esophagus (HP:0410151). HP:0410151 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:60030 SUPPORT Other
"HP:0410151 | Eosinophilic infiltration of the esophagus | Occasional (29-5%)"
Orphanet's curated HPO frequency annotation classifies eosinophilic infiltration of the esophagus as Occasional (29-5%) in Loeys-Dietz syndrome.
🧬

Genetic Associations

8
TGFBR1 Mutations (LDS Type 1) (Causative)
Show evidence (2 references)
PMID:16928994 SUPPORT Human Clinical
"We found a mutation in TGFBR1 or TGFBR2 in all probands with typical Loeys-Dietz syndrome (type I) and in 12 probands presenting with vascular Ehlers-Danlos syndrome (Loeys-Dietz syndrome type II)"
100% of typical LDS probands had TGFBR1 or TGFBR2 mutations.
ORPHA:60030 SUPPORT Other
"TGFBR1 | transforming growth factor beta receptor 1 | hgnc:11772 | Disease-causing germline mutation(s) in"
Orphanet curates TGFBR1 as a disease-causing gene for Loeys-Dietz syndrome.
Variants (2)
Missense mutations in kinase domain (TGFBR1)
Missense mutations in the intracellular kinase domain of TGFBR1 that impair receptor signaling.
Dominant-negative kinase-domain missense variants (e.g., K232R, R487P)
A subset of TGFBR1 missense variants, including K232R and R487P, do not simply inactivate the receptor but also interfere with the function of the co-expressed wild-type receptor, i.e. a dominant-negative effect layered on top of haploinsufficiency.
Show evidence (2 references)
PMID:40612107 SUPPORT In Vitro
"some mutations in TGFBR1, such as K232R and R487P, are not merely inactivating but also exert a dominant-negative impact on the function of the receptor in LDS"
This review reports that specific TGFBR1 kinase-domain missense variants (K232R, R487P) exert a dominant-negative effect on the wild-type receptor, distinct from simple haploinsufficiency. The underlying finding (Cardoso et al. 2012, cited directly below) is a cell-transfection functional assay, not a clinical observation, so this is graded IN_VITRO rather than HUMAN_CLINICAL.
PMID:22414221 SUPPORT In Vitro
"In co-transfection experiments with equal amounts wild-type receptor, the LDS mutations were found to confer a modest dominant negative effect."
Cardoso et al. 2012 is the primary study underlying the review's K232R/R487P claim above: seven LDS-associated TGFBR1 missense substitutions were tested by co-transfection with wild-type receptor in HEK293 cells, and a modest dominant-negative effect was measured. The cached abstract does not itself name the individual substitutions tested, so this item is cited to directly support the general dominant-negative finding rather than to independently confirm the K232R/R487P attribution.
TGFBR2 Mutations (LDS Type 2) (Causative)
Show evidence (3 references)
PMID:16928994 SUPPORT Human Clinical
"Mutations in either TGFBR1 or TGFBR2 predispose patients to aggressive and widespread vascular disease"
Loeys et al. establish TGFBR2 mutations as causative for LDS.
PMID:29270370 SUPPORT Human Clinical
"LDS type 2 TGFBR2 55–60%"
Sources the 55-60% share of LDS cases stated in these notes, from the review's LDS subtype table, which gives TGFBR1/LDS1 20-25% over the same series.
ORPHA:60030 SUPPORT Other
"TGFBR2 | transforming growth factor beta receptor 2 | hgnc:11773 | Disease-causing germline mutation(s) in"
Orphanet curates TGFBR2 as a disease-causing gene for Loeys-Dietz syndrome.
Variants (1)
Missense mutations in kinase domain (TGFBR2)
Missense mutations affecting the kinase domain of TGFBR2.
SMAD3 Mutations (LDS Type 3) (Causative)
Show evidence (2 references)
PMID:21217753 SUPPORT Human Clinical
"the disease is caused by mutations in SMAD3. This gene encodes a member of the TGF-beta pathway that is essential for TGF-beta signal transmission"
van de Laar et al. identified SMAD3 as the causal gene for the aneurysms-osteoarthritis syndrome (LDS type 3).
ORPHA:60030 SUPPORT Other
"SMAD3 | SMAD family member 3 | hgnc:6769 | Disease-causing germline mutation(s) in"
Orphanet curates SMAD3 as a disease-causing gene for Loeys-Dietz syndrome.
TGFB2 Mutations (LDS Type 4) (Causative)
Show evidence (2 references)
PMID:24577266 SUPPORT Human Clinical
"Chromosome deletions encompassing the TGFB2 gene (and hypothetically the SMAD3 gene) causing haploinsufficiency are sufficient to cause features of LDS"
MacCarrick et al. describe TGFB2 haploinsufficiency as sufficient for LDS features.
ORPHA:60030 SUPPORT Other
"TGFB2 | transforming growth factor beta 2 | hgnc:11768 | Disease-causing germline mutation(s) in"
Orphanet curates TGFB2 as a disease-causing gene for Loeys-Dietz syndrome.
TGFB3 Mutations (LDS Type 5) (Causative)
Show evidence (1 reference)
ORPHA:60030 SUPPORT Other
"TGFB3 | transforming growth factor beta 3 | hgnc:11769 | Disease-causing germline mutation(s) in"
Orphanet curates TGFB3 as a disease-causing gene for Loeys-Dietz syndrome.
SMAD2 Mutations (Causative)
Show evidence (1 reference)
ORPHA:60030 SUPPORT Other
"SMAD2 | SMAD family member 2 | hgnc:6768 | Disease-causing germline mutation(s) in"
Orphanet curates SMAD2 as a disease-causing gene for Loeys-Dietz syndrome.
IPO8 Mutations (Causative)
Show evidence (1 reference)
ORPHA:60030 SUPPORT Other
"IPO8 | importin 8 | hgnc:9853 | Disease-causing germline mutation(s) (loss of function) in"
Orphanet curates IPO8 as a disease-causing gene (loss of function) for Loeys-Dietz syndrome.
TGFBR1 (Pathogenic Variants)
Gene: TGFBR1 hgnc:11772 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is TGFBR1 (hgnc:11772). hgnc:11772 is a gene from the HUGO Gene Nomenclature Committee.
Show evidence (1 reference)
CGGV:assertion_8a546ce2-432c-4c8a-90e5-97293d7938be-2019-03-27T160000.000Z SUPPORT Other
"TGFBR1 | HGNC:11772 | Loeys-Dietz syndrome | MONDO:0018954 | AD | Definitive"
ClinGen classifies the TGFBR1-Loeys-Dietz syndrome gene-disease relationship as definitive with autosomal dominant inheritance.
🗃️

External Assertions

1
Orphanet Loeys-Dietz syndrome record
Orphanet Structured disease record ORPHA:60030
Orphanet structured record for Loeys-Dietz syndrome, including curated cross-references to MONDO, ICD-10, ICD-11, OMIM, MeSH, MedDRA, and UMLS identifiers.
Show evidence (3 references)
ORPHA:60030 SUPPORT Other
"MONDO:0018954 | Exact"
The Orphanet cross-reference table exactly maps ORPHA:60030 to MONDO:0018954.
ORPHA:60030 SUPPORT Other
"ICD-10:Q87.4 | Narrower"
The Orphanet cross-reference table maps ORPHA:60030 to ICD-10 Q87.4 with a Narrower mapping.
ORPHA:60030 SUPPORT Other
"UMLS:C2697932 | Exact"
The Orphanet cross-reference table exactly maps ORPHA:60030 to UMLS C2697932.
💊

Medical Actions

4
Prophylactic Aortic Root Replacement
Action: surgical procedureNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is surgical procedure (NCIT:C15329), qualified as located in aorta. NCIT:C15329 is a clinical intervention from the NCI Thesaurus. Ontology label: Surgical Procedure NCIT:C15329
Located in: aortaUberon multi-species anatomy ontology (UBERON) Relation: this treatment is delivered to this anatomical location This treatment is delivered to aorta (UBERON:0000947). UBERON:0000947 is an anatomical location from the Uberon multi-species anatomy ontology. UBERON:0000947
Valve-sparing aortic root replacement at lower thresholds than Marfan syndrome. For adults with LDS 1/2, surgical repair is recommended at 4.0 cm maximal aortic root dimension. For children, aggressive medication may delay surgery until aortic annulus reaches 2.0-2.2 cm.
Show evidence (2 references)
PMID:24577266 SUPPORT Human Clinical
"For adults with LDS 1 or 2, this includes surgical repair of the aortic root once the maximal dimension of the aortic root reaches 4.0 cm"
MacCarrick et al. recommend surgical threshold of 4.0 cm for adult LDS patients, lower than the 5.0 cm for Marfan syndrome.
PMID:16928994 SUPPORT Human Clinical
"There were 59 vascular surgeries in the cohort, with one death during the procedure. This low rate of intraoperative mortality distinguishes the Loeys-Dietz syndrome from vascular Ehlers-Danlos syndrome"
Low surgical mortality supports aggressive prophylactic surgery approach in LDS, unlike vascular EDS.
Losartan/ARB Therapy
Angiotensin receptor blockers (particularly losartan) are used to reduce TGF-beta signaling. Losartan was shown to prevent aortic aneurysm in a mouse model by antagonizing TGF-beta through AT1 receptor blockade. Optimal dosing: 2.0 mg/kg/day for children, 100 mg/day for adults.
Show evidence (2 references)
PMID:16601194 SUPPORT Model Organism
"aortic aneurysm in a mouse model of MFS is associated with increased TGF-beta signaling and can be prevented by TGF-beta antagonists such as TGF-beta-neutralizing antibody or the angiotensin II type 1 receptor (AT1) blocker, losartan"
Habashi et al. provide the mechanistic rationale for losartan therapy in TGF-beta pathway disorders.
PMID:24577266 SUPPORT Human Clinical
"Angiotensin receptor blockers may be particularly beneficial due to their effects on the TGF-beta signaling cascade"
Clinical guidelines support ARB use for their pathway-specific effects beyond blood pressure reduction.
Beta-Blocker Therapy
Beta-blockers to reduce hemodynamic stress on the aorta. Standard-of-care for syndromic aneurysm conditions, often used in combination with ARBs.
Show evidence (1 reference)
PMID:24577266 SUPPORT Human Clinical
"Beta-Blockade to reduce hemodynamic stress on the vasculature has been the standard-of-care treatment for individuals with syndromic aneurysm conditions"
Beta-blockers are established standard of care for LDS vascular management.
Comprehensive Vascular Surveillance
Regular MRA or CTA imaging of the entire arterial tree from head to pelvis, as aneurysms can occur throughout the vascular system. Full vascular imaging at initial evaluation and at 2-year intervals if no aneurysms identified.
Show evidence (2 references)
PMID:24577266 SUPPORT Human Clinical
"Diagnostic or baseline vascular imaging through magnetic resonance angiography or computerized tomography angiography with three-dimensional reconstruction of the head, neck, chest, abdomen, and pelvis should be performed"
MacCarrick et al. recommend comprehensive head-to-pelvis imaging for all LDS patients.
PMID:36334952 SUPPORT Other
"provides recommendations to guide clinicians in the diagnosis, genetic evaluation and family screening, medical therapy, endovascular and surgical treatment, and long-term surveillance of patients with aortic disease across its multiple clinical presentation subsets"
The 2022 ACC/AHA aortic disease guideline is the current society standard for long-term aortic surveillance and family screening governing the heritable thoracic aortopathy of Loeys-Dietz syndrome.
📈

Progression

1
Onset
Age: Antenatal to Infancy
Show evidence (1 reference)
ORPHA:60030 SUPPORT Other
"Age of onset: Antenatal"
Orphanet records antenatal as an age-of-onset category for Loeys-Dietz syndrome.
📊

Prevalence

2
General population
Point Prevalence 1.0 per 100,000 1–9 per 100,000
The prevalence estimate located in PubMed is based on clinical literature rather than population-wide ascertainment, but it gives a usable upper-bound estimate for this rare connective tissue disorder.
Show evidence (1 reference)
PMID:32339686 SUPPORT Human Clinical
"The prevalence of LDS is estimated to be less than 1 in 100,000."
This abstract provides an explicit prevalence estimate for Loeys-Dietz syndrome.
Worldwide (Orphanet)
Orphanet epidemiology record references the landmark Loeys et al. 2006 cohort with unknown point prevalence worldwide.
Show evidence (1 reference)
ORPHA:60030 SUPPORT Other
"Unknown | Worldwide | Point prevalence | ORPHANET_16928994[PMID"
Orphanet records worldwide point prevalence as unknown, referencing the landmark PMID:16928994 study.
🔀

Differential Diagnoses

1

Conditions with similar clinical presentations that must be differentiated from Loeys-Dietz Syndrome:

Marfan Syndrome MONDO:0007947
Overlapping Features Autosomal dominant connective tissue disorder caused by FBN1 mutations encoding fibrillin-1. It shares aortic root aneurysm, scoliosis, pectus deformity, arachnodactyly and increased aortic-wall TGF-beta signaling with Loeys-Dietz syndrome, and both conform to the aortopathy_tgfbeta_dysregulation module, making it the principal alternative diagnosis when an aortopathy with marfanoid habitus is evaluated.
Distinguishing Features
  • Ectopia lentis is a cardinal diagnostic feature of Marfan syndrome under the revised Ghent nosology and was absent in every proband of the original Loeys-Dietz cohort (0/16), so lens dislocation argues for Marfan syndrome.
  • Hypertelorism, bifid uvula or cleft palate, and generalized arterial tortuosity are characteristic of Loeys-Dietz syndrome and are not associated with Marfan syndrome.
  • Aneurysm and dissection in Loeys-Dietz syndrome occur at younger ages, at smaller aortic diameters, and throughout the arterial tree rather than being centered on the aortic root, warranting earlier surgical intervention than in Marfan syndrome.
  • Molecular testing is definitive - FBN1 in Marfan syndrome versus a TGF-beta pathway gene in Loeys-Dietz syndrome (TGFBR1, TGFBR2, SMAD3, TGFB2, TGFB3, SMAD2, IPO8).
Show evidence (5 references)
PMID:20591885 SUPPORT Human Clinical
"aortic root aneurysm and ectopia lentis are the cardinal clinical features"
The revised Ghent nosology makes ectopia lentis a cardinal Marfan criterion, providing the positive finding that redirects the differential away from Loeys-Dietz syndrome.
PMID:15731757 SUPPORT Human Clinical
"Ectopia lentis 0/16 (0%) Typical 1/15"
The original cohort's comparison table records ectopia lentis in 0 of 16 Loeys-Dietz probands while listing it as typical for Marfan syndrome.
PMID:16928994 SUPPORT Human Clinical
"The disease is characterized by the triad of arterial tortuosity and aneurysms, hypertelorism, and bifid uvula or cleft palate and is caused by heterozygous mutations in the genes encoding transforming growth factor beta receptors 1 and 2"
Establishes the craniofacial and vascular triad plus the TGFBR1/TGFBR2 etiology that separate Loeys-Dietz syndrome from FBN1-related Marfan syndrome.
+ 2 more references
🧫

Experimental Models

1
hiPSC-derived bioengineered vascular graft, TGFBR1 A230T (LDS Type 1) IPSC_DERIVED_MODEL
Bioengineered vascular grafts (BVGs) generated from isogenic control and CRISPR-edited or patient-derived hiPSC vascular smooth muscle cells carrying the TGFBR1 A230T (LDS type 1) pathogenic variant, implanted into the carotid arteries of nude rats to model aortic root aneurysm formation in an animal host.
Cell source
hiPSC-derived cardiovascular-progenitor-lineage vascular smooth muscle cells, both CRISPR-Cas9 gene-edited (isogenic TGFBR1 A230T/+) and patient-derived (with an isogenic gene-corrected control)
Culture
Bioengineered vascular graft implanted into nude rat carotid arteries
Publication
PMID:38718134
Pathograph links
Extracellular Matrix Degradation partially recapitulates fidelity: moderate TGFBR1 A230T bioengineered vascular grafts show defective extracellular-matrix gene expression, decreased collagen hydroxylation, and impaired smooth-muscle-cell organization. This overlaps this node's elastic-fiber-assembly arm (GO:0048251 DECREASED) and its net aortic-wall-weakening consequence, but the graft's dominant mechanism is defective ECM SYNTHESIS/maturation (reduced collagen-modifying enzyme activity) rather than the MMP-driven ECM DISASSEMBLY (GO:0022617 INCREASED) this node principally asserts, so the model is graded a partial recapitulation rather than a full one.
Limitations: Direction conflict: this node describes increased TGF-beta signaling driving MMP-mediated extracellular-matrix disassembly (GO:0022617 INCREASED), but PMID:38718134 evidences the opposite arm -- defective ECM synthesis, with reduced collagen-modifying enzyme activity (e.g. P4HA2, P3H1, PLOD1, LOX) and ECM-formation gene sets enriched in the corrected (not mutant) grafts, and lower TGF-beta signaling in mutant grafts than in corrected ones. Both readouts recorded below are DECREASED, not INCREASED, so they support this node's elastic-fiber-assembly (GO:0048251 DECREASED) arm and the general aortic-wall-weakening/medial-degeneration anchor (aortopathy_tgfbeta_dysregulation#Aortic Medial Degeneration and Wall Weakening) rather than the MMP-driven degradation arm the node otherwise centers on. The graft is also a bioengineered tissue-construct implant rather than a native aorta, and models a single TGFBR1 missense allele (A230T); generalization to other TGFBR1 kinase-domain variants is not established.
Readouts
Graft mechanical strength (burst pressure, suture retention)
Direction: DECREASED
Interpretation: TGFBR1 A230T grafts had lower burst pressure and suture retention strength than isogenic controls, a functional consequence of the underlying ECM defect.
Show evidence (1 reference)
PMID:38718134 SUPPORT In Vitro
"The TGFBR1A230T variant led to impaired mechanical properties of BVGs, resulting in lower burst pressure and suture retention strength."
Directly measures the weakened mechanical performance that results from the ECM defect this node models.
Collagen hydroxylation and ECM gene expression
Direction: DECREASED
Interpretation: Spatial transcriptomics and histology showed defective ECM-forming gene expression and decreased collagen hydroxylation in TGFBR1-A230T-mutant grafts and patient tissue.
Show evidence (1 reference)
PMID:38718134 SUPPORT In Vitro
"Histological analysis and protein assays validated quantitative and qualitative ECM defects in PatientA230T/+ BVGs and patient tissue, including decreased collagen hydroxylation."
Documents the specific ECM/collagen molecular defect underlying the mechanical weakening in this TGFBR1-genotype human model.
Show evidence (1 reference)
PMID:38718134 SUPPORT In Vitro
"highlighted the role of reduced collagen modifying enzyme activity in human TAA formation"
States the study's overall conclusion that reduced collagen-modifying enzyme activity, downstream of the TGFBR1 A230T variant, drives human thoracic aortic aneurysm formation, supporting this hiPSC graft model as informative for the ECM-degradation node.
🐁

Animal Models

1
Tgfbr1 M318R/+ knock-in mouse (LDS Type 1)
Species
Mouse
Genotype
Tgfbr1 M318R/+ knock-in (heterozygous kinase-domain missense)
Publication
PMID:24355923
Pathograph links
Paradoxical TGF-beta Signaling recapitulates fidelity: high A TGFBR1-specific (LDS type 1) knock-in mouse carrying the human M318R kinase-domain missense mutation recapitulates the LDS vascular phenotype, unlike simple Tgfbr1 haploinsufficiency, and reproduces the paradoxical in vivo increase in aortic-wall TGF-beta/SMAD2 signaling despite diminished receptor response to exogenous ligand in vitro.
Limitations: The knock-in strain models a single TGFBR1 kinase-domain missense allele (M318R); the same study also generated a parallel Tgfbr2 knock-in strain and a Tgfbr2-overexpressing transgenic line, so some reported findings (e.g. losartan responsiveness) reflect the shared LDS mechanism across both receptor genotypes rather than a TGFBR1-exclusive result.
Readouts
Aortic-wall Smad2 phosphorylation and TGF-beta target-gene output
Direction: INCREASED
Interpretation: Progressive upregulation of Smad2 phosphorylation and TGF-beta target-gene output in the aortic wall paralleled worsening aneurysm pathology in vivo, supporting a paradoxical signaling increase rather than the diminished signaling predicted from the receptor mutation alone.
Show evidence (1 reference)
PMID:24355923 SUPPORT Model Organism
"Analysis of TGF-β signaling in the aortic wall in vivo revealed progressive upregulation of Smad2 phosphorylation and TGF-β target gene output, which paralleled worsening of aneurysm pathology"
Directly measures the paradoxical in vivo TGF-beta/SMAD2 signaling increase this node asserts, in a TGFBR1 (LDS1) knock-in strain.
Show evidence (1 reference)
PMID:24355923 SUPPORT Model Organism
"Knockin and transgenic mice, but not haploinsufficient animals, recapitulated the LDS phenotype."
Establishes that the Tgfbr1 M318R/+ knock-in mouse, unlike a simple haploinsufficient allele, is an informative model of LDS vascular pathogenesis, consistent with the mixed haploinsufficiency/dominant-negative mechanism described for TGFBR1 kinase-domain variants.
{ }

Source YAML

click to show 
name: Loeys-Dietz Syndrome
creation_date: '2026-02-13T00:31:42Z'
category: Mendelian
description: >
  Loeys-Dietz syndrome (LDS) is an autosomal dominant connective tissue disorder
  caused by heterozygous mutations in genes encoding components of the TGF-beta
  signaling pathway, most commonly TGFBR1 and TGFBR2. It is characterized by the
  triad of arterial tortuosity and aneurysms, hypertelorism, and bifid uvula or
  cleft palate. Additional features include craniosynostosis, skeletal abnormalities
  (scoliosis, pectus deformity, joint laxity or contractures), thin translucent skin,
  and immunologic features (food allergy, eosinophilic gastrointestinal disease).
  LDS carries a high risk of aortic dissection at smaller aortic diameters than
  Marfan syndrome, with a mean age at death of 26.0 years in initial cohorts.
  Early diagnosis and aggressive surgical management are critical.
disease_term:
  preferred_term: Loeys-Dietz syndrome
  term:
    id: MONDO:0018954
    label: Loeys-Dietz syndrome
mappings:
  mondo_mappings:
  # LDS1 (TGFBR1) and LDS2 (TGFBR2) have no standalone dismech entry, so their
  # MONDO leaf classes are only reachable via has_subtypes[].subtype_term below;
  # declaring them here too lets scripts/grouping_mondo_gaps.py's descendant-
  # coverage index (which reads disease_term/mappings, not has_subtypes) see
  # them as covered. LDS3/4/5/6 are NOT repeated here: each already has its own
  # standalone entry (Aneurysm-Osteoarthritis_Syndrome, Loeys-Dietz_Syndrome_4,
  # Rienhoff_Syndrome, Loeys-Dietz_Syndrome_6) whose own disease_term already
  # indexes that MONDO id, so adding it here too would be redundant. See #8866.
  - term:
      id: MONDO:0012212
      label: Loeys-Dietz syndrome 1
    mapping_predicate: skos:narrowMatch
    mapping_source: MONDO
    mapping_justification: TGFBR1-related Loeys-Dietz syndrome; covered by the Type 1 subtype of this umbrella entry, which is the sole dismech locus for this leaf class.
  - term:
      id: MONDO:0012427
      label: Loeys-Dietz syndrome 2
    mapping_predicate: skos:narrowMatch
    mapping_source: MONDO
    mapping_justification: TGFBR2-related Loeys-Dietz syndrome; covered by the Type 2 subtype of this umbrella entry, which is the sole dismech locus for this leaf class.
classifications:
  isds_skeletal_category:
  - classification_value: overgrowth_syndromes_with_skeletal_involvement
    notes: >-
      ISDS Nosology and Classification of Genetic Skeletal Disorders, 2019
      revision (Mortier et al., PMID:31633310), Table 1 group 30 "Overgrowth (tall
      stature) syndromes with skeletal involvement"; listed as "Loeys-Dietz
      syndrome (types 1-6)".
definitions:
- name: Orphanet disease definition
  definition_type: CASE_DEFINITION
  description: >
    Orphanet defines Loeys-Dietz syndrome as a rare genetic connective tissue
    disorder characterized by a broad spectrum of craniofacial, vascular and
    skeletal manifestations with four genetic subtypes described forming a
    clinical continuum.
  evidence:
  - reference: ORPHA:60030
    reference_title: "Loeys-Dietz syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Loeys-Dietz syndrome is a rare genetic connective tissue disorder characterized by a broad spectrum of craniofacial, vascular and skeletal manifestations with four genetic subtypes described forming a clinical continuum."
    explanation: Orphanet's definition supports the multisystem connective-tissue framing of this entry.
external_assertions:
- name: Orphanet Loeys-Dietz syndrome record
  source: Orphanet
  assertion_type: Structured disease record
  external_id: ORPHA:60030
  url: http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=60030
  description: >
    Orphanet structured record for Loeys-Dietz syndrome, including curated
    cross-references to MONDO, ICD-10, ICD-11, OMIM, MeSH, MedDRA, and UMLS
    identifiers.
  evidence:
  - reference: ORPHA:60030
    reference_title: "Loeys-Dietz syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "MONDO:0018954 | Exact"
    explanation: The Orphanet cross-reference table exactly maps ORPHA:60030 to MONDO:0018954.
  - reference: ORPHA:60030
    reference_title: "Loeys-Dietz syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "ICD-10:Q87.4 | Narrower"
    explanation: The Orphanet cross-reference table maps ORPHA:60030 to ICD-10 Q87.4 with a Narrower mapping.
  - reference: ORPHA:60030
    reference_title: "Loeys-Dietz syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "UMLS:C2697932 | Exact"
    explanation: The Orphanet cross-reference table exactly maps ORPHA:60030 to UMLS C2697932.
parents:
- Connective Tissue Disorders
- Marfan and Marfan-related Disorders
has_subtypes:
- name: Loeys-Dietz Syndrome Type 1
  display_name: Loeys-Dietz Syndrome Type 1 (TGFBR1)
  subtype_term:
    preferred_term: Loeys-Dietz syndrome 1
    term:
      id: MONDO:0012212
      label: Loeys-Dietz syndrome 1
  genes:
  - preferred_term: TGFBR1
    term:
      id: hgnc:11772
      label: TGFBR1
  subtype_frequency: "20-25%"
  description: >
    Caused by heterozygous mutations in TGFBR1, encoding the TGF-beta
    receptor type I kinase; most mutations cluster in the intracellular
    serine/threonine kinase domain and act through a mixture of
    haploinsufficiency and dominant-negative interference with the
    wild-type receptor rather than a single uniform mechanism. Often
    presents with more severe craniofacial features including
    craniosynostosis. Earlier cardiovascular surgery (mean age 16.9 years)
    and death (22.6 years) compared to type 2. Despite this, aortic
    specimens from TGFBR1-mutated individuals show a milder grade of
    cystic medial necrosis at histopathology than TGFBR2-mutated
    specimens, and a gene-based severity ranking places LDS1 among the
    more severe subtypes together with LDS2 (LDS1 = LDS2 > LDS3 > LDS4 >
    LDS5).
  evidence:
  - reference: PMID:40612107
    reference_title: "Decoding clinical diversity in monogenic TGFBR1 and TGFBR2 mutations: insights into the interplay of molecular mechanisms and hypomorphicity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      a splice donor site variation in intron 5 (c.973 + 1 G>A) in a
      familial case of LDS was defined
    explanation: >-
      This review reports the clinical/genetic identification of a
      TGFBR1 splice-donor variant (c.973+1G>A) in a familial LDS case.
      This snippet establishes only that identification; the same source
      explicitly contrasts this specific variant against
      haploinsufficiency and instead anticipates a dominant-negative
      mechanism for it (see the COMPUTATIONAL evidence item immediately
      below).
  - reference: PMID:40612107
    reference_title: "Decoding clinical diversity in monogenic TGFBR1 and TGFBR2 mutations: insights into the interplay of molecular mechanisms and hypomorphicity."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: >-
      It is anticipated that this mutation will have a dominant-negative
      effect by causing the in-frame deletion of exon five within the
      STK domain
    explanation: >-
      The dominant-negative consequence of this splice-donor variant is
      described as "anticipated" -- a predicted structural effect of the
      in-frame exon-5 deletion on the kinase domain, not a directly
      measured receptor-interference result, so this is graded as an
      inferred/predicted claim rather than direct clinical or
      experimental evidence.
  - reference: PMID:33408307
    reference_title: "Surgical Outcome and Histological Differences between Individuals with TGFBR1 and TGFBR2 Mutations in Loeys-Dietz Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All patients with TGFBR2 mutations revealed grade III cystic medial
      necrosis (CMN), whereas 67% of patients with TGFBR1 mutations
      showed CMN (p = 0.033) and only one patient had grade III (p
      <0.001).
    explanation: >-
      Comparative histopathology of surgical aortic specimens shows that
      TGFBR1-mutated (LDS1) aortas have a milder grade of cystic medial
      necrosis than TGFBR2-mutated (LDS2) aortas, a histological
      distinction between the two most common LDS subtypes.
  - reference: PMID:31569402
    reference_title: "Genotypic Categorization of Loeys-Dietz Syndrome Based on 24 Novel Families and Literature Data."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This advised the subdivision of LDS into multiple classes based on
      the causative gene (LDS1-5) providing a general indication of the
      spectrum of disease severity, from most to least severe form:
      LDS1=LDS2>LDS3>LDS4>LDS5
    explanation: >-
      Establishes the gene-based severity ranking that places TGFBR1-related
      LDS1 among the two most severe LDS subtypes.
- name: Loeys-Dietz Syndrome Type 2
  display_name: Loeys-Dietz Syndrome Type 2 (TGFBR2)
  subtype_term:
    preferred_term: Loeys-Dietz syndrome 2
    term:
      id: MONDO:0012427
      label: Loeys-Dietz syndrome 2
  genes:
  - preferred_term: TGFBR2
    term:
      id: hgnc:11773
      label: TGFBR2
  subtype_frequency: "55-60%"
  description: >
    Caused by heterozygous mutations in TGFBR2, encoding the TGF-beta receptor
    type II. Characterized kinase-domain variants impair canonical SMAD2/3
    signaling and act through dominant-negative interference with the receptor
    complex rather than simple haploinsufficiency, which a Tgfbr2 knockin mouse
    corroborates in vivo. Aortic disease is severe: aortic specimens from
    TGFBR2-mutated individuals show uniformly higher-grade cystic medial
    necrosis than TGFBR1-mutated specimens, a paediatric TGFBR2 cohort showed
    larger aortic z-scores and stiffer, less distensible aortas at the annulus,
    sinotubular junction and ascending aorta than its TGFBR1 comparator, and the
    gene-based severity ranking places LDS2 alongside LDS1 as the most severe
    classes (LDS1 = LDS2 > LDS3 > LDS4 > LDS5). Female TGFBR2 carriers were a
    higher-risk group for aortic dissection after initial surgery in one
    surgical series. An allele-specific ocular association has been reported for
    TGFBR2 Arg528 missense variants, which in two cases produced a familial
    exudative vitreoretinopathy-like retinal phenotype; this is not established
    as a general LDS2 feature. Two older descriptive claims are retained from
    the original entry but must be read with their provenance: "more prominent
    cutaneous features and phenotypic overlap with vascular Ehlers-Danlos
    syndrome", and later cardiovascular surgery (mean age 26.9 years) and death
    (31.8 years) than type 1, both derive from Loeys et al. 2006's
    *clinically* defined type II cohort - selected for a vascular-Ehlers-Danlos-like,
    craniofacially spared presentation - and not from a TGFBR2-genotyped cohort.
    They should not be read as showing that TGFBR2 disease is milder or
    craniofacially spared: the paediatric genotyped comparison above found
    craniofacial features similar in the TGFBR1 and TGFBR2 groups. Nosology
    note: "type 2" has a modern gene-based sense (the TGFBR2 class of the LDS1-6
    gene series, used here and by MONDO:0012427 / OMIM:610168) and an older
    gene-agnostic clinical sense from Loeys et al. 2006; see review_notes for
    why MONDO's free-text definition still names both receptor genes.
  review_notes: >-
    Gene-binding rationale, recorded so the MONDO free-text definition is not
    re-inherited by a later curator. MONDO:0012427's definition, imported from
    NCIT:C114768, states the disorder is "caused by mutations in either the
    TGFBR1 or TGFBR2 gene", which conflicts with OMIM:610168 being the TGFBR2
    entry. The conflict is a stale-import artifact, not a real disagreement.
    MONDO's logical definition is unambiguous - intersection_of MONDO:0018954
    and RO:0004003 some HGNC:11773 - and it carries the
    MONDO:patterns/disease_series_by_gene synonyms "TGFBR2 Loeys-Dietz syndrome"
    and "Loeys-Dietz syndrome caused by mutation in TGFBR2", plus xref
    OMIM:610168. The free-text prose instead preserves the older clinical sense
    of "Loeys-Dietz syndrome type II" from Loeys et al. 2006 (PMID:16928994),
    which denoted a craniofacially spared, vascular-Ehlers-Danlos-like
    presentation and was explicitly gene-agnostic - probands of both clinical
    types carried TGFBR1 or TGFBR2 mutations. That is why the definition names
    both genes. dismech binds this subtype to TGFBR2, following the logical
    definition, the OMIM xref and the gene series.
  evidence:
  - reference: PMID:16928994
    reference_title: "Aneurysm syndromes caused by mutations in the TGF-beta receptor."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We found a mutation in TGFBR1 or TGFBR2 in all probands with typical
      Loeys-Dietz syndrome (type I) and in 12 probands presenting with
      vascular Ehlers-Danlos syndrome (Loeys-Dietz syndrome type II)
    explanation: >-
      Sources the historical, purely clinical sense of "Loeys-Dietz syndrome
      type II" - a vascular-Ehlers-Danlos-like presentation - and shows it was
      gene-agnostic, with probands of both types carrying TGFBR1 or TGFBR2
      mutations. This is the origin of the "either TGFBR1 or TGFBR2" wording in
      MONDO:0012427's imported free-text definition, recorded here so the
      historical clinical sense is not mistaken for the modern gene-based one
      this subtype is bound to.
  - reference: PMID:16928994
    reference_title: "Aneurysm syndromes caused by mutations in the TGF-beta receptor."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patients with Loeys-Dietz syndrome type I, as compared with those with
      type II, underwent cardiovascular surgery earlier (mean age, 16.9 years
      vs. 26.9 years) and died earlier (22.6 years vs. 31.8 years)
    explanation: >-
      Sources the mean age at cardiovascular surgery (26.9 years) and at death
      (31.8 years) quoted in this subtype description. These figures come from
      the clinically defined type II cohort quoted in the item above, not from a
      TGFBR2-genotyped cohort, which is why the description flags their
      provenance rather than presenting them as a TGFBR2 genotype effect.
  - reference: PMID:33408307
    reference_title: "Surgical Outcome and Histological Differences between Individuals with TGFBR1 and TGFBR2 Mutations in Loeys-Dietz Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All patients with TGFBR2 mutations revealed grade III cystic medial
      necrosis (CMN), whereas 67% of patients with TGFBR1 mutations showed CMN
    explanation: >-
      Comparative histopathology of surgical aortic specimens shows uniformly
      grade III cystic medial necrosis in TGFBR2-mutated (LDS2) aortas against
      a lower grade in TGFBR1-mutated specimens, supporting the more severe
      medial degeneration attributed to LDS2 here.
  - reference: PMID:33408307
    reference_title: "Surgical Outcome and Histological Differences between Individuals with TGFBR1 and TGFBR2 Mutations in Loeys-Dietz Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The freedom from aortic dissection (AD) after the initial surgery was also
      lower in female patients with TGFBR2 mutation than in other patients (p =
      0.025)
    explanation: >-
      Supports the sex-specific dissection risk stated in the description, and
      is quoted from the RESULTS rather than the abstract conclusion on purpose.
      Graded PARTIAL because this is a subanalysis of six female TGFBR2 patients
      in a single-centre series of 22. The paper's conclusion also asserts that
      reoperation was more frequent in this group, but its own results report
      that comparison as a non-significant trend (p = 0.08, log-rank) with no
      difference between the TGFBR1 and TGFBR2 groups overall (p = 0.19), so the
      reoperation half of that conclusion is deliberately not curated here.
  - reference: PMID:38774681
    reference_title: "Impact of Genotype-Phenotype Interactions on Cardiovascular Function in Paediatric Loeys-Dietz Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Paediatric LDS patients with TGFBR2 present with more severe
      cardiovascular phenotypes than patients with TGFBR1 with larger aortic
      dimensions and increased aortic stiffness
    explanation: >-
      A paediatric echocardiographic cohort (TGFBR1 n = 17 vs TGFBR2 n = 15)
      supports the larger aortic dimensions and increased aortic stiffness
      attributed to LDS2 relative to LDS1. Single-centre and retrospective, so
      the description attributes it to one cohort rather than generalizing.
  - reference: PMID:38774681
    reference_title: "Impact of Genotype-Phenotype Interactions on Cardiovascular Function in Paediatric Loeys-Dietz Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patients with TGFBR2 also had significantly lower aortic distensibility
      and strain coupled with higher stiffness index at the level of the
      annulus, sinotubular junction, and ascending aorta
    explanation: >-
      Sources the reduced-distensibility half of the aortic-mechanics claim,
      which the summary conclusion quote above does not itself quantify. The
      quote is carried to its anatomical qualifier because the effect was found
      at the annulus, sinotubular junction and ascending aorta, not throughout
      the aorta.
  - reference: PMID:38774681
    reference_title: "Impact of Genotype-Phenotype Interactions on Cardiovascular Function in Paediatric Loeys-Dietz Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The presence of arterial tortuosity, craniofacial features, pectus
      deformities, dural ectasia, and scoliosis was similar between the groups
    explanation: >-
      Supports the caveat that TGFBR2 disease should not be treated as
      craniofacially spared. In this genotyped paediatric comparison
      craniofacial features were similar in the TGFBR1 and TGFBR2 groups, which
      is the counterweight to inheriting the craniofacially spared framing of
      Loeys 2006's clinically defined type II into a gene-defined TGFBR2 block.
  - reference: PMID:29270370
    reference_title: "Differences in manifestations of Marfan syndrome, Ehlers-Danlos syndrome, and Loeys-Dietz syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "LDS type 2 TGFBR2 55–60%"
    explanation: >-
      Sources the subtype_frequency recorded on this subtype. The review's LDS
      subtype table gives TGFBR2/LDS2 the largest share of the gene-defined
      series at 55-60%, against 20-25% for TGFBR1/LDS1 - the same figures the
      sibling LDS1 subtype and the TGFBR2 genetic block carry, so the three are
      now consistent and traceable to a cached primary source.
  - reference: PMID:31569402
    reference_title: "Genotypic Categorization of Loeys-Dietz Syndrome Based on 24 Novel Families and Literature Data."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The majority of variants affected the TGFBR1 (9/24) and TGFBR2 (10/24) genes"
    explanation: >-
      Independent single-cohort corroboration that TGFBR2 is the most frequently
      affected LDS gene: 10 of 24 novel families, about 42%, the largest
      single-gene share in that series. Recorded as consistent with, not as the
      source of, the 55-60% subtype_frequency, which comes from the
      PMID:29270370 subtype table.
  - reference: PMID:31569402
    reference_title: "Genotypic Categorization of Loeys-Dietz Syndrome Based on 24 Novel Families and Literature Data."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "from most to least severe form: LDS1=LDS2>LDS3>LDS4>LDS5"
    explanation: >-
      Sources the gene-based severity ranking that places LDS2 alongside LDS1 as
      the most severe of the gene-defined LDS classes, the counterweight to the
      later-event figures from the clinically defined type II cohort. Graded
      PARTIAL because this paper is restating a ranking it attributes to an
      earlier reference rather than deriving it, and it also concludes that a
      phenotypic continuum with significant TGFBR1/TGFBR2 overlap emerges as
      more patients are described.
  - reference: PMID:28679693
    reference_title: "Functional validation reveals the novel missense V419L variant in TGFBR2 associated with Loeys-Dietz syndrome (LDS) impairs canonical TGF-beta signaling."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      V419L significantly delayed SMAD2 phosphorylation by western blot and
      significantly decreased TGF-β-induced gene transcription by reporter
      assays consistent with known pathogenic variants in this gene
    explanation: >-
      Cell-based functional validation of a TGFBR2 kinase-domain variant
      (c.1255G>T, p.Val419Leu) supports the impaired canonical SMAD2/3 signaling
      attributed to characterized kinase-domain TGFBR2 mutations here.
  - reference: PMID:21098638
    reference_title: "Quantitative analysis of TGFBR2 mutations in Marfan-syndrome-related disorders suggests a correlation between phenotypic severity and Smad signaling activity."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      A dominant-negative effect was demonstrated for mutations associated
      with LDS and MFS2
    explanation: >-
      Quantitative signaling assays across nine TGFBR2 mutations support the
      dominant-negative mechanism attributed to LDS2 here, in preference to
      simple haploinsufficiency.
  - reference: PMID:24355923
    reference_title: "Angiotensin II-dependent TGF-beta signaling contributes to Loeys-Dietz syndrome vascular pathogenesis."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      We generated 2 knockin mouse strains with LDS mutations in either Tgfbr1
      or Tgfbr2 and a transgenic mouse overexpressing mutant Tgfbr2. Knockin and
      transgenic mice, but not haploinsufficient animals, recapitulated the LDS
      phenotype
    explanation: >-
      Knockin and transgenic animals reproduce the LDS phenotype while
      haploinsufficient animals do not, corroborating in vivo that LDS is not a
      simple loss-of-one-copy mechanism. The quote is carried back to the
      sentence naming the strains so it is visible that a Tgfbr1 knockin was
      generated alongside the Tgfbr2 knockin and transgenic, and that this
      sentence does not by itself isolate TGFBR2. Model-organism evidence,
      offered only as mechanistic corroboration of the dominant-negative claim,
      not as support for any human phenotype.
  - reference: PMID:41024485
    reference_title: "A genotype to phenotype relationship of exudative vitreoretinopathy in Loeys-Dietz syndrome due to a pathogenic variant in TGFBR2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This is the second reported case of a missense variant at the amino acid
      residue 528 (Arg528) of TGFBR2 that results in a FEVR-like phenotype in
      a LDS patient
    explanation: >-
      Sources the allele-specific ocular association stated in the description -
      TGFBR2 Arg528 missense variants and a familial-exudative-vitreoretinopathy-like
      retinal phenotype. Graded PARTIAL because the association rests on only
      two reported cases at this residue and is not established as a general
      LDS2 feature; it is curated as an allele-specific observation, not a
      subtype-level phenotype.
- name: Loeys-Dietz Syndrome Type 3
  display_name: Loeys-Dietz Syndrome Type 3 (SMAD3)
  subtype_term:
    preferred_term: aneurysm-osteoarthritis syndrome
    term:
      id: MONDO:0013426
      label: aneurysm-osteoarthritis syndrome
  genes:
  - preferred_term: SMAD3
    term:
      id: hgnc:6769
      label: SMAD3
  description: >
    Caused by mutations in SMAD3. Associated with early-onset osteoarthritis
    (aneurysms-osteoarthritis syndrome) and increased prevalence of mitral
    valve prolapse.
  review_notes: >-
    Full curation for this subtype (phenotypes, pathophysiology, evidence)
    lives in the standalone entry `kb/disorders/Aneurysm-Osteoarthritis_Syndrome.yaml`
    (MONDO:0013426), which predates and is richer than this row. This stub is
    kept as a term-bound cross-reference rather than duplicated content while
    the umbrella-vs-standalone authoritative locus for per-type LDS detail
    remains an open curation decision.
- name: Loeys-Dietz Syndrome Type 4
  display_name: Loeys-Dietz Syndrome Type 4 (TGFB2)
  subtype_term:
    preferred_term: Loeys-Dietz syndrome 4
    term:
      id: MONDO:0013897
      label: Loeys-Dietz syndrome 4
  genes:
  - preferred_term: TGFB2
    term:
      id: hgnc:11768
      label: TGFB2
  description: >
    Caused by heterozygous mutations in TGFB2. The vascular course is
    generally milder and later-onset than TGFBR1/TGFBR2-related disease
    (aneurysms typically apparent in the fourth decade), but articular and
    skeletal involvement is prevalent and can dominate the presentation even
    in the absence of any vascular event.
  evidence:
  - reference: PMID:25163805
    reference_title: "Further delineation of Loeys-Dietz syndrome type 4 in a family with mild vascular involvement and a TGFB2 splicing mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      loss-of-function mutations in TGFB2 gene do not always lead to
      aggressive vascular phenotypes and that articular and skeletal signs
      are prevalent
    explanation: >-
      Corrects a prior version of this stub, which stated LDS4 has "lower
      prevalence of musculoskeletal involvement" - the transposed opposite of
      this paper's conclusion: articular/skeletal signs are prevalent and can
      be the only presenting feature, while it is the vascular phenotype that
      is comparatively mild.
  review_notes: >-
    Full curation for this subtype lives in the standalone entry
    `kb/disorders/Loeys-Dietz_Syndrome_4.yaml` (MONDO:0013897). This stub is
    kept as a term-bound cross-reference while the umbrella-vs-standalone
    authoritative locus for per-type LDS detail remains an open curation
    decision.
- name: Loeys-Dietz Syndrome Type 5
  display_name: Loeys-Dietz Syndrome Type 5 (TGFB3)
  subtype_term:
    preferred_term: Rienhoff syndrome
    term:
      id: MONDO:0014262
      label: Rienhoff syndrome
  genes:
  - preferred_term: TGFB3
    term:
      id: hgnc:11769
      label: TGFB3
  description: >
    Caused by mutations in TGFB3. Milder phenotype with variable penetrance.
  review_notes: >-
    Full curation for this subtype lives in the standalone entry
    `kb/disorders/Rienhoff_Syndrome.yaml` (MONDO:0014262). This stub is kept
    as a term-bound cross-reference while the umbrella-vs-standalone
    authoritative locus for per-type LDS detail remains an open curation
    decision.
- name: Loeys-Dietz Syndrome Type 6
  display_name: Loeys-Dietz Syndrome Type 6 (SMAD2)
  subtype_term:
    preferred_term: Loeys-Dietz syndrome 6
    term:
      id: MONDO:0030500
      label: Loeys-Dietz syndrome 6
  genes:
  - preferred_term: SMAD2
    term:
      id: hgnc:6768
      label: SMAD2
  description: >
    Caused by heterozygous mutations in SMAD2, an intracellular TGF-beta
    signaling effector paralogous to SMAD3 (Type 3/AOS). Previously absent
    from this umbrella's has_subtypes list entirely.
  review_notes: >-
    Full curation for this subtype lives in the standalone entry
    `kb/disorders/Loeys-Dietz_Syndrome_6.yaml` (MONDO:0030500). This row is
    added to close a gap: LDS6 had no has_subtypes entry at all. Kept as a
    term-bound cross-reference while the umbrella-vs-standalone authoritative
    locus for per-type LDS detail remains an open curation decision.
inheritance:
- name: Autosomal Dominant
  description: >
    Autosomal dominant inheritance with variable expressivity.
  evidence:
  - reference: PMID:24577266
    reference_title: "Loeys-Dietz syndrome: a primer for diagnosis and management."
    supports: SUPPORT
    snippet: >-
      LDS, an autosomal-dominant connective tissue disorder first
      characterized by aortic aneurysms and generalized arterial tortuosity,
      hypertelorism, and bifid/broad uvula or cleft palate
    explanation: >-
      MacCarrick et al. confirm autosomal dominant inheritance in this
      comprehensive clinical management review.
  - reference: ORPHA:60030
    reference_title: "Loeys-Dietz syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Autosomal dominant"
    explanation: Orphanet records autosomal dominant inheritance for Loeys-Dietz syndrome.
- name: Autosomal Recessive
  description: >
    Rare autosomal recessive inheritance has been reported for Loeys-Dietz
    syndrome, per Orphanet curation.
  evidence:
  - reference: ORPHA:60030
    reference_title: "Loeys-Dietz syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Autosomal recessive"
    explanation: Orphanet records autosomal recessive as an additional inheritance pattern for Loeys-Dietz syndrome.
prevalence:
- population: General population
  measure_type: POINT_PREVALENCE
  prevalence_class: BAND_1_9_PER_100000
  rate_per_100000: 1.0
  percentage: less than 1 in 100,000
  notes: >-
    The prevalence estimate located in PubMed is based on clinical literature
    rather than population-wide ascertainment, but it gives a usable upper-bound
    estimate for this rare connective tissue disorder.
  evidence:
  - reference: PMID:32339686
    reference_title: "Type A Aortic Dissection Caused by Loeys-Dietz Syndrome with Novel Variation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The prevalence of LDS is estimated to be less than 1 in 100,000.
    explanation: >-
      This abstract provides an explicit prevalence estimate for Loeys-Dietz
      syndrome.
- population: Worldwide (Orphanet)
  notes: >-
    Orphanet epidemiology record references the landmark Loeys et al. 2006
    cohort with unknown point prevalence worldwide.
  evidence:
  - reference: ORPHA:60030
    reference_title: "Loeys-Dietz syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Unknown | Worldwide | Point prevalence | ORPHANET_16928994[PMID"
    explanation: Orphanet records worldwide point prevalence as unknown, referencing the landmark PMID:16928994 study.
progression:
- phase: Onset
  age_range: Antenatal to Infancy
  evidence:
  - reference: ORPHA:60030
    reference_title: "Loeys-Dietz syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Age of onset: Antenatal"
    explanation: Orphanet records antenatal as an age-of-onset category for Loeys-Dietz syndrome.
pathophysiology:
- name: Paradoxical TGF-beta Signaling
  conforms_to: "aortopathy_tgfbeta_dysregulation#TGF-beta Signaling Dysregulation"
  description: >
    Loss-of-function mutations in TGF-beta receptors paradoxically lead to
    increased TGF-beta signaling in the aortic wall, mediated through
    non-canonical pathways and compensatory upregulation. This results in
    excessive SMAD2/3 phosphorylation and activation of ERK and p38 MAPK
    downstream targets that promote extracellular matrix degradation.
  cell_types:
  - preferred_term: Vascular Smooth Muscle Cell
    term:
      id: CL:0000359
      label: vascular associated smooth muscle cell
  - preferred_term: Fibroblast
    term:
      id: CL:0000057
      label: fibroblast
  biological_processes:
  - preferred_term: TGF-beta Signaling
    term:
      id: GO:0007179
      label: transforming growth factor beta receptor signaling pathway
    modifier: INCREASED
  - preferred_term: SMAD Signaling
    term:
      id: GO:0060395
      label: SMAD protein signal transduction
    modifier: INCREASED
  downstream:
  - target: Extracellular Matrix Degradation
    description: >-
      Enhanced TGF-beta/SMAD signaling drives matrix metalloproteinase
      upregulation and degradation of the aortic wall extracellular matrix.
  evidence:
  - reference: PMID:21493862
    reference_title: "Noncanonical TGFβ signaling contributes to aortic aneurysm progression in Marfan syndrome mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      extracellular signal-regulated kinase (ERK) 1 and 2 and Smad2
      are activated in a mouse model of MFS, and both are inhibited by
      therapies directed against TGFbeta
    explanation: >-
      Holm et al. demonstrate that both canonical (Smad2) and noncanonical
      (ERK1/2) TGF-beta signaling are activated in aortic disease, and
      selective ERK1/2 inhibition ameliorates aortic growth while Smad4
      deficiency exacerbates disease.
  - reference: PMID:16928994
    reference_title: "Aneurysm syndromes caused by mutations in the TGF-beta receptor."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The disease is characterized by the triad of arterial tortuosity and
      aneurysms, hypertelorism, and bifid uvula or cleft palate and is
      caused by heterozygous mutations in the genes encoding transforming
      growth factor beta receptors 1 and 2 (TGFBR1 and TGFBR2, respectively)
    explanation: >-
      The landmark Loeys et al. 2006 NEJM paper establishes TGF-beta receptor
      mutations as the cause and defines the clinical triad.
- name: Noncanonical MAPK Pathway Activation
  description: >
    In addition to canonical SMAD signaling, noncanonical ERK1/2 and JNK
    pathways are prominently activated in LDS aortic tissue. Selective
    inhibition of ERK1/2 ameliorates aortic growth, while JNK antagonism
    is also protective. These non-SMAD pathways may be the primary
    drivers of aortic disease progression.
  biological_processes:
  - preferred_term: ERK Cascade
    term:
      id: GO:0070371
      label: ERK1 and ERK2 cascade
  - preferred_term: JNK Cascade
    term:
      id: GO:0007254
      label: JNK cascade
  evidence:
  - reference: PMID:21493862
    reference_title: "Noncanonical TGFβ signaling contributes to aortic aneurysm progression in Marfan syndrome mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      noncanonical (Smad-independent) TGFbeta signaling is a prominent driver
      of aortic disease in MFS mice, and inhibition of the ERK1/2 or JNK1
      pathways is a potential therapeutic strategy for the disease
    explanation: >-
      Holm et al. establish noncanonical TGF-beta signaling via ERK and JNK
      as key drivers of aortic aneurysm progression.
- name: Extracellular Matrix Degradation
  conforms_to: "aortopathy_tgfbeta_dysregulation#Aortic Medial Degeneration and Wall Weakening"
  description: >
    Enhanced TGF-beta signaling leads to upregulation of matrix
    metalloproteinases (MMPs) and reduced expression of tissue inhibitors,
    causing degradation of elastic fibers and collagen in the arterial wall.
    This weakens the vessel wall leading to aneurysm formation and dissection.
  cell_types:
  - preferred_term: vascular associated smooth muscle cell
    term:
      id: CL:0000359
      label: vascular associated smooth muscle cell
  biological_processes:
  - preferred_term: Extracellular Matrix Disassembly
    term:
      id: GO:0022617
      label: extracellular matrix disassembly
    modifier: INCREASED
  - preferred_term: Elastic Fiber Assembly
    term:
      id: GO:0048251
      label: elastic fiber assembly
    modifier: DECREASED
  locations:
  - preferred_term: Aorta
    term:
      id: UBERON:0000947
      label: aorta
  evidence:
  - reference: PMID:18852674
    reference_title: "Histopathologic findings in ascending aortas from individuals with Loeys-Dietz syndrome (LDS)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      LDS samples had increased medial collagen and a subtle but diffuse form of
      elastic fiber fragmentation and extracellular matrix deposition, referred
      to as diffuse medial degeneration.
    explanation: >-
      Histopathology of ascending aortic root tissue from 15 LDS patients
      documents diffuse medial degeneration with elastic-fiber fragmentation,
      supporting the elastin-integrity loss and wall weakening this node
      asserts. Graded PARTIAL because the same study reports *increased* medial
      collagen and extracellular-matrix *deposition* (fibrosis), not net
      collagen loss — so it supports the elastic-fiber-degradation arm but not a
      collagen-degradation reading of this node.
  - reference: PMID:18852674
    reference_title: "Histopathologic findings in ascending aortas from individuals with Loeys-Dietz syndrome (LDS)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      an immunohistochemical stain for pSmad2, a marker of TGFbeta activity, was
      significantly increased in LDS patients compared with controls
    explanation: >-
      Increased pSmad2 in LDS aortic tissue confirms the enhanced TGF-beta
      signaling that this node identifies as the upstream driver of the medial
      ECM remodeling.
  - reference: PMID:36606286
    reference_title: "Markers of extracellular matrix remodeling and systemic inflammation in patients with heritable thoracic aortic diseases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All groups of HTAD patients had increased levels matrix
      metalloproteinase-9 (MMP-9) as compared with healthy controls, also in
      adjusted analyses, reflecting altered ECM remodeling.
    explanation: >-
      A heritable-thoracic-aortic-disease cohort including 12 Loeys-Dietz
      patients shows increased circulating MMP-9 versus controls, directly
      evidencing the matrix-metalloproteinase upregulation this node asserts;
      the authors conclude "upregulated MMP-9, a matrix degrading enzyme, is a
      common feature of several subgroups of HTAD."
  downstream:
  - target: Aortic Aneurysm
    description: >-
      Degradation of elastic fibers and collagen weakens the aortic media,
      promoting aneurysmal dilation.
  - target: Aortic Dissection
    description: >-
      Progressive medial weakening predisposes to dissection, characteristically
      at smaller aortic diameters than in Marfan syndrome.
  - target: Aortic Root Aneurysm
  - target: Arterial Dissection
  - target: Arterial Tortuosity
  - target: Pregnancy-Related Vascular Complications
  - target: Patent Ductus Arteriosus
  - target: Uterine Rupture
  - target: Mitral Regurgitation
  - target: Spontaneous Pneumothorax
  - target: Translucent Skin
  - target: Striae Distensae
  - target: Atypical Scarring of Skin
  - target: Bruising Susceptibility
- name: Skeletal Development Disruption
  description: >
    TGF-beta signaling is critical for skeletal development, particularly
    in suture closure and vertebral column formation. Dysregulated signaling
    leads to craniosynostosis, scoliosis, and cervical spine instability.
    Cervical spine findings are prominent in LDS 1/2 (51% of patients).
  biological_processes:
  - preferred_term: Skeletal System Development
    term:
      id: GO:0001501
      label: skeletal system development
  - preferred_term: Cranial Suture Morphogenesis
    term:
      id: GO:0060363
      label: cranial suture morphogenesis
  evidence:
  - reference: PMID:24577266
    reference_title: "Loeys-Dietz syndrome: a primer for diagnosis and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Cervical spine findings are prominent features in LDS 1/2 (51%),
      but presence in LDS 3 and 4 is unknown
    explanation: >-
      MacCarrick et al. document cervical spine abnormalities in over
      half of LDS type 1/2 patients.
  downstream:
  - target: Hypertelorism
  - target: Bifid Uvula
  - target: Cleft Palate
  - target: Craniosynostosis
  - target: Scoliosis
  - target: Pectus Excavatum
  - target: Joint Hypermobility
  - target: Cervical Spine Instability
  - target: Clubfoot
  - target: Osteoporosis
  - target: Early-Onset Osteoarthritis
  - target: Tall Stature
  - target: Malar Flattening
  - target: Micrognathia
  - target: Blue Sclerae
  - target: Arachnodactyly
  - target: Camptodactyly
  - target: Pes Planus
  - target: Joint Dislocation
  - target: Myopia
- name: Immune Dysregulation
  description: >
    LDS is associated with a high prevalence of immunologic features
    including food allergy (31%), eosinophilic gastrointestinal disease,
    asthma, eczema, and allergic rhinitis. TGF-beta pathway disruption
    affects immune regulation and mucosal tolerance.
  biological_processes:
  - preferred_term: Immune Response Regulation
    term:
      id: GO:0050776
      label: regulation of immune response
  evidence:
  - reference: PMID:24577266
    reference_title: "Loeys-Dietz syndrome: a primer for diagnosis and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      LDS has been associated with a high prevalence of immunologic features
      including asthma, food allergy, eczema, and allergic rhinitis
    explanation: >-
      MacCarrick et al. document significant immune dysregulation in LDS,
      with food allergy prevalence of 31% compared to 6-8% in the
      general population.
  downstream:
  - target: Food Allergy
  - target: Asthma
  - target: Eczematoid Dermatitis
  - target: Eosinophilic Esophageal Infiltration
phenotypes:
- name: Aortic Aneurysm
  description: >
    Progressive aortic aneurysm, a hallmark vascular feature. Orphanet classifies
    aortic aneurysm as Very frequent (99-80%) in LDS.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Aortic aneurysm
    term:
      id: HP:0004942
      label: Aortic aneurysm
  evidence:
  - reference: PMID:16928994
    reference_title: "Aneurysm syndromes caused by mutations in the TGF-beta receptor."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The natural history of both types was characterized by aggressive
      arterial aneurysms (mean age at death, 26.0 years) and a high
      incidence of pregnancy-related complications (in 6 of 12 women)
    explanation: >-
      Loeys et al. document aggressive aneurysmal disease with early mortality
      in 52 families with LDS.
  - reference: ORPHA:60030
    reference_title: "Loeys-Dietz syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0004942 | Aortic aneurysm | Very frequent (99-80%)"
    explanation: Orphanet's curated HPO frequency annotation classifies aortic aneurysm as Very frequent (99-80%) in Loeys-Dietz syndrome.
- name: Aortic Root Aneurysm
  description: >
    Progressive dilation of the aortic root, occurring at earlier ages and
    smaller diameters than in Marfan syndrome. Dissections have occurred
    at aortic dimensions of 3.9-4.0 cm, unlike the 5.0 cm threshold
    in Marfan syndrome.
  phenotype_term:
    preferred_term: Aortic root aneurysm
    term:
      id: HP:0002616
      label: Aortic root aneurysm
  evidence:
  - reference: PMID:24577266
    reference_title: "Loeys-Dietz syndrome: a primer for diagnosis and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      dissections have occurred in individuals with LDS 1, 2, or 3 at
      aortic dimensions of 3.9-4.0 cm
    explanation: >-
      MacCarrick et al. note dissections at smaller diameters than Marfan
      syndrome, supporting more aggressive surgical thresholds.
- name: Aortic Dissection
  description: >
    Aortic dissection is a life-threatening complication occurring at smaller
    aortic diameters than in Marfan syndrome. Orphanet classifies this as
    Very frequent (99-80%).
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Aortic dissection
    term:
      id: HP:0002647
      label: Aortic dissection
  evidence:
  - reference: PMID:16928994
    reference_title: "Aneurysm syndromes caused by mutations in the TGF-beta receptor."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The natural history of both types was characterized by aggressive
      arterial aneurysms (mean age at death, 26.0 years) and a high
      incidence of pregnancy-related complications (in 6 of 12 women)
    explanation: >-
      Loeys et al. document aggressive aneurysmal disease leading to
      dissection and early mortality.
  - reference: ORPHA:60030
    reference_title: "Loeys-Dietz syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002647 | Aortic dissection | Very frequent (99-80%)"
    explanation: Orphanet's curated HPO frequency annotation classifies aortic dissection as Very frequent (99-80%) in Loeys-Dietz syndrome.
- name: Arterial Tortuosity
  description: >
    Widespread arterial tortuosity, particularly of the head and neck
    vessels. A distinguishing feature from Marfan syndrome. Increased
    vertebral arterial tortuosity is a marker of adverse aortic outcome.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Arterial tortuosity
    term:
      id: HP:0005116
      label: Arterial tortuosity
  evidence:
  - reference: PMID:35662564
    reference_title: "Clinical features and complications of Loeys-Dietz syndrome: A systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the most commonly reported features and complications being: aortic
      aneurysms and dissections, arterial tortuosity, high arched palate,
      abnormal uvula and hypertelorism
    explanation: >-
      Systematic review of 3896 LDS cases confirms arterial tortuosity
      as one of the most common features.
  - reference: ORPHA:60030
    reference_title: "Loeys-Dietz syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0005116 | Arterial tortuosity | Very frequent (99-80%)"
    explanation: Orphanet's curated HPO frequency annotation classifies arterial tortuosity as Very frequent (99-80%) in Loeys-Dietz syndrome.
- name: Arterial Dissection
  description: >
    Dissection can occur in arteries throughout the body, not just the aorta.
    Orphanet classifies arterial dissection as Very frequent (99-80%).
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Arterial dissection
    term:
      id: HP:0005294
      label: Arterial dissection
  evidence:
  - reference: ORPHA:60030
    reference_title: "Loeys-Dietz syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0005294 | Arterial dissection | Very frequent (99-80%)"
    explanation: Orphanet's curated HPO frequency annotation classifies arterial dissection as Very frequent (99-80%) in Loeys-Dietz syndrome.
- name: Hypertelorism
  description: >
    Wide-spaced eyes, part of the characteristic craniofacial gestalt
    and the diagnostic triad.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Hypertelorism
    term:
      id: HP:0000316
      label: Hypertelorism
  evidence:
  - reference: PMID:16928994
    reference_title: "Aneurysm syndromes caused by mutations in the TGF-beta receptor."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The disease is characterized by the triad of arterial tortuosity and
      aneurysms, hypertelorism, and bifid uvula or cleft palate
    explanation: >-
      Hypertelorism is part of the defining diagnostic triad.
  - reference: ORPHA:60030
    reference_title: "Loeys-Dietz syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000316 | Hypertelorism | Frequent (79-30%)"
    explanation: Orphanet's curated HPO frequency annotation classifies hypertelorism as Frequent (79-30%) in Loeys-Dietz syndrome.
- name: Bifid Uvula
  description: >
    Bifid or broad uvula, a hallmark feature often used for clinical
    screening. May range from broad uvula to overt cleft palate.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Bifid uvula
    term:
      id: HP:0000193
      label: Bifid uvula
  evidence:
  - reference: PMID:16928994
    reference_title: "Aneurysm syndromes caused by mutations in the TGF-beta receptor."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The disease is characterized by the triad of arterial tortuosity and
      aneurysms, hypertelorism, and bifid uvula or cleft palate
    explanation: >-
      Bifid uvula is part of the defining diagnostic triad.
  - reference: ORPHA:60030
    reference_title: "Loeys-Dietz syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000193 | Bifid uvula | Frequent (79-30%)"
    explanation: Orphanet's curated HPO frequency annotation classifies bifid uvula as Frequent (79-30%) in Loeys-Dietz syndrome.
- name: Cleft Palate
  description: >
    Cleft palate, ranging from submucous to overt, is part of the
    craniofacial spectrum of LDS.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Cleft palate
    term:
      id: HP:0000175
      label: Cleft palate
  evidence:
  - reference: ORPHA:60030
    reference_title: "Loeys-Dietz syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000175 | Cleft palate | Frequent (79-30%)"
    explanation: Orphanet's curated HPO frequency annotation classifies cleft palate as Frequent (79-30%) in Loeys-Dietz syndrome.
- name: Craniosynostosis
  description: >
    Premature fusion of cranial sutures, most commonly the sagittal suture
    but also coronal, metopic, and squamosal. More common in LDS type 1.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Craniosynostosis
    term:
      id: HP:0001363
      label: Craniosynostosis
  evidence:
  - reference: PMID:24577266
    reference_title: "Loeys-Dietz syndrome: a primer for diagnosis and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Most commonly, the sagittal suture is prematurely closed, but the
      coronal, metopic, and squamosal sutures can also be involved
    explanation: >-
      MacCarrick et al. describe the pattern of suture involvement in LDS
      craniosynostosis.
  - reference: ORPHA:60030
    reference_title: "Loeys-Dietz syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001363 | Craniosynostosis | Frequent (79-30%)"
    explanation: Orphanet's curated HPO frequency annotation classifies craniosynostosis as Frequent (79-30%) in Loeys-Dietz syndrome.
- name: Scoliosis
  description: >
    Progressive scoliosis requiring monitoring and potential surgical
    intervention.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Scoliosis
    term:
      id: HP:0002650
      label: Scoliosis
  evidence:
  - reference: ORPHA:60030
    reference_title: "Loeys-Dietz syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002650 | Scoliosis | Frequent (79-30%)"
    explanation: Orphanet's curated HPO frequency annotation classifies scoliosis as Frequent (79-30%) in Loeys-Dietz syndrome.
- name: Pectus Excavatum
  description: >
    Pectus excavatum or pectus carinatum, similar to Marfan syndrome.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Pectus excavatum
    term:
      id: HP:0000767
      label: Pectus excavatum
  evidence:
  - reference: PMID:24577266
    reference_title: "Loeys-Dietz syndrome: a primer for diagnosis and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Skeletal features in all types of LDS can show overlap with Marfan
      syndrome, including pectus deformity, scoliosis, and flat feet
    explanation: >-
      Pectus deformity confirmed across all LDS types in clinical review.
  - reference: ORPHA:60030
    reference_title: "Loeys-Dietz syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000767 | Pectus excavatum | Occasional (29-5%)"
    explanation: Orphanet's curated HPO frequency annotation classifies pectus excavatum as Occasional (29-5%) in Loeys-Dietz syndrome.
- name: Joint Hypermobility
  description: >
    Generalized joint hypermobility, contributing to joint dislocations
    and chronic pain. Extremity contractures in conjunction with joint
    hyperextension are unusual in the general population but common in LDS.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Joint hypermobility
    term:
      id: HP:0001382
      label: Joint hypermobility
  evidence:
  - reference: PMID:24577266
    reference_title: "Loeys-Dietz syndrome: a primer for diagnosis and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Extremity contractures in conjunction with joint hyperextension are
      unusual in the general population but common in LDS
    explanation: >-
      The coexistence of contractures and hypermobility is a distinctive
      feature of LDS.
  - reference: ORPHA:60030
    reference_title: "Loeys-Dietz syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001382 | Joint hypermobility | Frequent (79-30%)"
    explanation: Orphanet's curated HPO frequency annotation classifies joint hypermobility as Frequent (79-30%) in Loeys-Dietz syndrome.
- name: Cervical Spine Instability
  description: >
    Cervical spine instability or malformation present in 51% of LDS 1/2
    patients. Requires assessment with flexion-extension X-rays.
  phenotype_term:
    preferred_term: Cervical spine instability
    term:
      id: HP:0010646
      label: Cervical spine instability
  evidence:
  - reference: PMID:24577266
    reference_title: "Loeys-Dietz syndrome: a primer for diagnosis and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Cervical spine findings are prominent features in LDS 1/2 (51%)
    explanation: >-
      Over half of LDS type 1/2 patients have cervical spine abnormalities.
- name: Translucent Skin
  description: >
    Thin, velvety, translucent skin with easy bruising and visible veins.
    Scars may be atrophic and wound healing delayed.
  phenotype_term:
    preferred_term: Translucent skin
    term:
      id: HP:0010648
      label: Dermal translucency
  evidence:
  - reference: PMID:24577266
    reference_title: "Loeys-Dietz syndrome: a primer for diagnosis and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Cutaneous findings in LDS include velvety, thin, translucent skin
      with easy bruising and visible veins
    explanation: >-
      MacCarrick et al. describe the cutaneous features of LDS.
- name: Clubfoot
  description: >
    Talipes equinovarus, present in a proportion of individuals.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Clubfoot
    term:
      id: HP:0001762
      label: Talipes equinovarus
  evidence:
  - reference: ORPHA:60030
    reference_title: "Loeys-Dietz syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001762 | Talipes equinovarus | Frequent (79-30%)"
    explanation: Orphanet's curated HPO frequency annotation classifies talipes equinovarus as Frequent (79-30%) in Loeys-Dietz syndrome.
- name: Osteoporosis
  description: >
    Low bone mineral density and skeletal fragility, with at least 60%
    of patients having low or very low bone mineral density.
  phenotype_term:
    preferred_term: Osteoporosis
    term:
      id: HP:0000939
      label: Osteoporosis
  evidence:
  - reference: PMID:24577266
    reference_title: "Loeys-Dietz syndrome: a primer for diagnosis and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      at least 60% of patients had low or very low bone mineral density
      in the spine, hip, and/or femoral neck
    explanation: >-
      High fracture risk and low BMD documented in LDS patients.
- name: Food Allergy
  description: >
    High prevalence of food allergies (31% versus 6-8% in general
    population), with most common allergens being eggs, milk, soy,
    peanuts, and tree nuts.
  phenotype_term:
    preferred_term: Food allergy
    term:
      id: HP:0500093
      label: Food allergy
  evidence:
  - reference: PMID:24577266
    reference_title: "Loeys-Dietz syndrome: a primer for diagnosis and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A conservative prevalence estimate of food allergies in this population
      is 31% (compared with 6-8% prevalence in the general population)
    explanation: >-
      Food allergy prevalence is approximately 4-5 times higher in LDS
      than in the general population.
- name: Early-Onset Osteoarthritis
  description: >
    Particularly prominent in LDS type 3 (SMAD3 mutations). Most affected
    individuals present with early-onset osteoarthritis with osteochondritis
    dissecans, onset as early as age 12.
  phenotype_term:
    preferred_term: Osteoarthritis
    term:
      id: HP:0002758
      label: Osteoarthritis
  evidence:
  - reference: PMID:21217753
    reference_title: "Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In contrast with other aneurysm syndromes, most of these affected
      individuals presented with early-onset osteoarthritis
    explanation: >-
      van de Laar et al. identified SMAD3 mutations as cause of
      aneurysms-osteoarthritis syndrome.
  - reference: PMID:35662564
    reference_title: "Clinical features and complications of Loeys-Dietz syndrome: A systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      LDS Type 3 demonstrated an increased prevalence of mitral valve
      prolapse and arthritis
    explanation: >-
      Systematic review confirms LDS type 3 association with arthritis.
- name: Pregnancy-Related Vascular Complications
  description: >
    High incidence of pregnancy-related complications including aortic
    dissection. Among 222 women with 522 pregnancies in a systematic review,
    4% experienced aortic dissection with 1% peripartum mortality.
  phenotype_term:
    preferred_term: Pregnancy complications
    term:
      id: HP:0001197
      label: Abnormality of prenatal development or birth
  evidence:
  - reference: PMID:16928994
    reference_title: "Aneurysm syndromes caused by mutations in the TGF-beta receptor."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      a high incidence of pregnancy-related complications (in 6 of 12 women)
    explanation: >-
      50% pregnancy complication rate in initial LDS cohort.
  - reference: PMID:35662564
    reference_title: "Clinical features and complications of Loeys-Dietz syndrome: A systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Amongst 222 women who underwent 522 pregnancies, 4% experienced an
      aortic dissection and the peripartum mortality rate was 1%
    explanation: >-
      Large systematic review quantifies pregnancy risks in LDS.
- name: Tall Stature
  description: >
    Tall stature is a frequent skeletal feature of LDS, consistent with
    the connective tissue disorder spectrum.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Tall stature
    term:
      id: HP:0000098
      label: Tall stature
  evidence:
  - reference: ORPHA:60030
    reference_title: "Loeys-Dietz syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000098 | Tall stature | Frequent (79-30%)"
    explanation: Orphanet's curated HPO frequency annotation classifies tall stature as Frequent (79-30%) in Loeys-Dietz syndrome.
- name: Malar Flattening
  description: >
    Malar flattening is a craniofacial feature of LDS.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Malar flattening
    term:
      id: HP:0000272
      label: Malar flattening
  evidence:
  - reference: ORPHA:60030
    reference_title: "Loeys-Dietz syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000272 | Malar flattening | Frequent (79-30%)"
    explanation: Orphanet's curated HPO frequency annotation classifies malar flattening as Frequent (79-30%) in Loeys-Dietz syndrome.
- name: Micrognathia
  description: >
    Micrognathia (small jaw) is part of the craniofacial phenotype of LDS.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Micrognathia
    term:
      id: HP:0000347
      label: Micrognathia
  evidence:
  - reference: ORPHA:60030
    reference_title: "Loeys-Dietz syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000347 | Micrognathia | Frequent (79-30%)"
    explanation: Orphanet's curated HPO frequency annotation classifies micrognathia as Frequent (79-30%) in Loeys-Dietz syndrome.
- name: Blue Sclerae
  description: >
    Blue sclerae reflecting connective tissue thinning of the sclera.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Blue sclerae
    term:
      id: HP:0000592
      label: Blue sclerae
  evidence:
  - reference: ORPHA:60030
    reference_title: "Loeys-Dietz syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000592 | Blue sclerae | Frequent (79-30%)"
    explanation: Orphanet's curated HPO frequency annotation classifies blue sclerae as Frequent (79-30%) in Loeys-Dietz syndrome.
- name: Arachnodactyly
  description: >
    Abnormally long, slender fingers, a skeletal feature shared with
    Marfan syndrome.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Arachnodactyly
    term:
      id: HP:0001166
      label: Arachnodactyly
  evidence:
  - reference: ORPHA:60030
    reference_title: "Loeys-Dietz syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001166 | Arachnodactyly | Frequent (79-30%)"
    explanation: Orphanet's curated HPO frequency annotation classifies arachnodactyly as Frequent (79-30%) in Loeys-Dietz syndrome.
- name: Eczematoid Dermatitis
  description: >
    Eczema is part of the immunologic/allergic phenotype of LDS.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Eczematoid dermatitis
    term:
      id: HP:0000964
      label: Eczematoid dermatitis
  evidence:
  - reference: ORPHA:60030
    reference_title: "Loeys-Dietz syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000964 | Eczematoid dermatitis | Frequent (79-30%)"
    explanation: Orphanet's curated HPO frequency annotation classifies eczematoid dermatitis as Frequent (79-30%) in Loeys-Dietz syndrome.
- name: Striae Distensae
  description: >
    Stretch marks (striae) reflecting connective tissue fragility.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Striae distensae
    term:
      id: HP:0001065
      label: Striae distensae
  evidence:
  - reference: ORPHA:60030
    reference_title: "Loeys-Dietz syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001065 | Striae distensae | Frequent (79-30%)"
    explanation: Orphanet's curated HPO frequency annotation classifies striae distensae as Frequent (79-30%) in Loeys-Dietz syndrome.
- name: Atypical Scarring of Skin
  description: >
    Abnormal scarring pattern reflecting connective tissue fragility.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Atypical scarring of skin
    term:
      id: HP:0000987
      label: Atypical scarring of skin
  evidence:
  - reference: ORPHA:60030
    reference_title: "Loeys-Dietz syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000987 | Atypical scarring of skin | Frequent (79-30%)"
    explanation: Orphanet's curated HPO frequency annotation classifies atypical scarring of skin as Frequent (79-30%) in Loeys-Dietz syndrome.
- name: Camptodactyly
  description: >
    Permanent flexion contracture of fingers, part of the skeletal phenotype.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Camptodactyly of finger
    term:
      id: HP:0100490
      label: Camptodactyly of finger
  evidence:
  - reference: ORPHA:60030
    reference_title: "Loeys-Dietz syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0100490 | Camptodactyly of finger | Frequent (79-30%)"
    explanation: Orphanet's curated HPO frequency annotation classifies camptodactyly of finger as Frequent (79-30%) in Loeys-Dietz syndrome.
- name: Patent Ductus Arteriosus
  description: >
    Patent ductus arteriosus is a congenital cardiovascular feature.
    Orphanet classifies this as Very frequent (99-80%).
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Patent ductus arteriosus
    term:
      id: HP:0001643
      label: Patent ductus arteriosus
  evidence:
  - reference: ORPHA:60030
    reference_title: "Loeys-Dietz syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001643 | Patent ductus arteriosus | Very frequent (99-80%)"
    explanation: Orphanet's curated HPO frequency annotation classifies patent ductus arteriosus as Very frequent (99-80%) in Loeys-Dietz syndrome.
- name: Pes Planus
  description: >
    Flat feet, a common skeletal feature shared with Marfan syndrome.
    Orphanet classifies this as Very frequent (99-80%).
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Pes planus
    term:
      id: HP:0001763
      label: Pes planus
  evidence:
  - reference: PMID:24577266
    reference_title: "Loeys-Dietz syndrome: a primer for diagnosis and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Skeletal features in all types of LDS can show overlap with Marfan
      syndrome, including pectus deformity, scoliosis, and flat feet
    explanation: >-
      MacCarrick et al. confirm flat feet across all LDS types.
  - reference: ORPHA:60030
    reference_title: "Loeys-Dietz syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001763 | Pes planus | Very frequent (99-80%)"
    explanation: Orphanet's curated HPO frequency annotation classifies pes planus as Very frequent (99-80%) in Loeys-Dietz syndrome.
- name: Uterine Rupture
  description: >
    Uterine rupture during pregnancy, reflecting connective tissue fragility
    of the uterine wall. Orphanet classifies this as Very frequent (99-80%).
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Uterine rupture
    term:
      id: HP:0100718
      label: Uterine rupture
  evidence:
  - reference: ORPHA:60030
    reference_title: "Loeys-Dietz syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0100718 | Uterine rupture | Very frequent (99-80%)"
    explanation: Orphanet's curated HPO frequency annotation classifies uterine rupture as Very frequent (99-80%) in Loeys-Dietz syndrome.
- name: Asthma
  description: >
    Asthma is part of the immunologic/allergic phenotype of LDS.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Asthma
    term:
      id: HP:0002099
      label: Asthma
  evidence:
  - reference: PMID:24577266
    reference_title: "Loeys-Dietz syndrome: a primer for diagnosis and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      LDS has been associated with a high prevalence of immunologic features
      including asthma, food allergy, eczema, and allergic rhinitis
    explanation: >-
      MacCarrick et al. document asthma as part of the immunologic phenotype.
  - reference: ORPHA:60030
    reference_title: "Loeys-Dietz syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002099 | Asthma | Frequent (79-30%)"
    explanation: Orphanet's curated HPO frequency annotation classifies asthma as Frequent (79-30%) in Loeys-Dietz syndrome.
- name: Myopia
  description: >
    Myopia (nearsightedness) is an occasional ocular feature.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Myopia
    term:
      id: HP:0000545
      label: Myopia
  evidence:
  - reference: ORPHA:60030
    reference_title: "Loeys-Dietz syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000545 | Myopia | Occasional (29-5%)"
    explanation: Orphanet's curated HPO frequency annotation classifies myopia as Occasional (29-5%) in Loeys-Dietz syndrome.
- name: Bruising Susceptibility
  description: >
    Easy bruising reflecting vascular and connective tissue fragility.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Bruising susceptibility
    term:
      id: HP:0000978
      label: Bruising susceptibility
  evidence:
  - reference: ORPHA:60030
    reference_title: "Loeys-Dietz syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000978 | Bruising susceptibility | Occasional (29-5%)"
    explanation: Orphanet's curated HPO frequency annotation classifies bruising susceptibility as Occasional (29-5%) in Loeys-Dietz syndrome.
- name: Mitral Regurgitation
  description: >
    Mitral valve insufficiency, an occasional cardiac feature.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Mitral regurgitation
    term:
      id: HP:0001653
      label: Mitral regurgitation
  evidence:
  - reference: ORPHA:60030
    reference_title: "Loeys-Dietz syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001653 | Mitral regurgitation | Occasional (29-5%)"
    explanation: Orphanet's curated HPO frequency annotation classifies mitral regurgitation as Occasional (29-5%) in Loeys-Dietz syndrome.
- name: Spontaneous Pneumothorax
  description: >
    Spontaneous pneumothorax, an occasional pulmonary feature.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Spontaneous pneumothorax
    term:
      id: HP:0002108
      label: Spontaneous pneumothorax
  evidence:
  - reference: ORPHA:60030
    reference_title: "Loeys-Dietz syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002108 | Spontaneous pneumothorax | Occasional (29-5%)"
    explanation: Orphanet's curated HPO frequency annotation classifies spontaneous pneumothorax as Occasional (29-5%) in Loeys-Dietz syndrome.
- name: Joint Dislocation
  description: >
    Joint dislocation reflecting ligamentous laxity.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Joint dislocation
    term:
      id: HP:0001373
      label: Joint dislocation
  evidence:
  - reference: ORPHA:60030
    reference_title: "Loeys-Dietz syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001373 | Joint dislocation | Occasional (29-5%)"
    explanation: Orphanet's curated HPO frequency annotation classifies joint dislocation as Occasional (29-5%) in Loeys-Dietz syndrome.
- name: Eosinophilic Esophageal Infiltration
  description: >
    Eosinophilic infiltration of the esophagus, part of the allergic/
    eosinophilic gastrointestinal disease spectrum in LDS.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Eosinophilic infiltration of the esophagus
    term:
      id: HP:0410151
      label: Eosinophilic infiltration of the esophagus
  evidence:
  - reference: ORPHA:60030
    reference_title: "Loeys-Dietz syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0410151 | Eosinophilic infiltration of the esophagus | Occasional (29-5%)"
    explanation: Orphanet's curated HPO frequency annotation classifies eosinophilic infiltration of the esophagus as Occasional (29-5%) in Loeys-Dietz syndrome.
genetic:
- name: TGFBR1 Mutations (LDS Type 1)
  association: Causative
  subtype: Loeys-Dietz Syndrome Type 1
  notes: >
    Heterozygous mutations in TGFBR1 encoding TGF-beta receptor type I.
    Most mutations cluster in the serine/threonine kinase domain. Accounts
    for 20-25% of LDS cases. Pathogenic variants act through a mixture of
    haploinsufficiency and, for a subset of kinase-domain missense
    variants, dominant-negative interference with the wild-type receptor.
  variants:
  - name: Missense mutations in kinase domain (TGFBR1)
    description: >
      Missense mutations in the intracellular kinase domain of TGFBR1
      that impair receptor signaling.
  - name: Dominant-negative kinase-domain missense variants (e.g., K232R, R487P)
    description: >
      A subset of TGFBR1 missense variants, including K232R and R487P, do
      not simply inactivate the receptor but also interfere with the
      function of the co-expressed wild-type receptor, i.e. a
      dominant-negative effect layered on top of haploinsufficiency.
    evidence:
    - reference: PMID:40612107
      reference_title: "Decoding clinical diversity in monogenic TGFBR1 and TGFBR2 mutations: insights into the interplay of molecular mechanisms and hypomorphicity."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        some mutations in TGFBR1, such as K232R and R487P, are not merely
        inactivating but also exert a dominant-negative impact on the
        function of the receptor in LDS
      explanation: >-
        This review reports that specific TGFBR1 kinase-domain missense
        variants (K232R, R487P) exert a dominant-negative effect on the
        wild-type receptor, distinct from simple haploinsufficiency. The
        underlying finding (Cardoso et al. 2012, cited directly below) is
        a cell-transfection functional assay, not a clinical observation,
        so this is graded IN_VITRO rather than HUMAN_CLINICAL.
    - reference: PMID:22414221
      reference_title: "TGFBR1 mutations associated with Loeys-Dietz syndrome are inactivating."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        In co-transfection experiments with equal amounts wild-type
        receptor, the LDS mutations were found to confer a modest
        dominant negative effect.
      explanation: >-
        Cardoso et al. 2012 is the primary study underlying the review's
        K232R/R487P claim above: seven LDS-associated TGFBR1 missense
        substitutions were tested by co-transfection with wild-type
        receptor in HEK293 cells, and a modest dominant-negative effect
        was measured. The cached abstract does not itself name the
        individual substitutions tested, so this item is cited to
        directly support the general dominant-negative finding rather
        than to independently confirm the K232R/R487P attribution.
  evidence:
  - reference: PMID:16928994
    reference_title: "Aneurysm syndromes caused by mutations in the TGF-beta receptor."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We found a mutation in TGFBR1 or TGFBR2 in all probands with typical
      Loeys-Dietz syndrome (type I) and in 12 probands presenting with
      vascular Ehlers-Danlos syndrome (Loeys-Dietz syndrome type II)
    explanation: >-
      100% of typical LDS probands had TGFBR1 or TGFBR2 mutations.
  - reference: ORPHA:60030
    reference_title: "Loeys-Dietz syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "TGFBR1 | transforming growth factor beta receptor 1 | hgnc:11772 | Disease-causing germline mutation(s) in"
    explanation: Orphanet curates TGFBR1 as a disease-causing gene for Loeys-Dietz syndrome.
- name: TGFBR2 Mutations (LDS Type 2)
  association: Causative
  subtype: Loeys-Dietz Syndrome Type 2
  notes: >
    Heterozygous mutations in TGFBR2 encoding TGF-beta receptor type II.
    Mutations primarily affect the kinase domain. Most common genetic cause,
    accounting for 55-60% of LDS cases.
  variants:
  - name: Missense mutations in kinase domain (TGFBR2)
    description: >
      Missense mutations affecting the kinase domain of TGFBR2.
  evidence:
  - reference: PMID:16928994
    reference_title: "Aneurysm syndromes caused by mutations in the TGF-beta receptor."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Mutations in either TGFBR1 or TGFBR2 predispose patients to
      aggressive and widespread vascular disease
    explanation: >-
      Loeys et al. establish TGFBR2 mutations as causative for LDS.
  - reference: PMID:29270370
    reference_title: "Differences in manifestations of Marfan syndrome, Ehlers-Danlos syndrome, and Loeys-Dietz syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "LDS type 2 TGFBR2 55–60%"
    explanation: >-
      Sources the 55-60% share of LDS cases stated in these notes, from the
      review's LDS subtype table, which gives TGFBR1/LDS1 20-25% over the same
      series.
  - reference: ORPHA:60030
    reference_title: "Loeys-Dietz syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "TGFBR2 | transforming growth factor beta receptor 2 | hgnc:11773 | Disease-causing germline mutation(s) in"
    explanation: Orphanet curates TGFBR2 as a disease-causing gene for Loeys-Dietz syndrome.
- name: SMAD3 Mutations (LDS Type 3)
  association: Causative
  subtype: Loeys-Dietz Syndrome Type 3
  notes: >
    Heterozygous mutations in SMAD3, an intracellular mediator of
    TGF-beta signaling. Associated with aneurysms-osteoarthritis syndrome.
  evidence:
  - reference: PMID:21217753
    reference_title: "Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the disease is caused by mutations in SMAD3. This gene encodes
      a member of the TGF-beta pathway that is essential for TGF-beta
      signal transmission
    explanation: >-
      van de Laar et al. identified SMAD3 as the causal gene for
      the aneurysms-osteoarthritis syndrome (LDS type 3).
  - reference: ORPHA:60030
    reference_title: "Loeys-Dietz syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "SMAD3 | SMAD family member 3 | hgnc:6769 | Disease-causing germline mutation(s) in"
    explanation: Orphanet curates SMAD3 as a disease-causing gene for Loeys-Dietz syndrome.
- name: TGFB2 Mutations (LDS Type 4)
  association: Causative
  subtype: Loeys-Dietz Syndrome Type 4
  notes: >
    Heterozygous mutations in TGFB2 encoding TGF-beta 2 ligand.
    Chromosome deletions encompassing TGFB2 causing haploinsufficiency
    are sufficient to cause LDS features.
  evidence:
  - reference: PMID:24577266
    reference_title: "Loeys-Dietz syndrome: a primer for diagnosis and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Chromosome deletions encompassing the TGFB2 gene (and hypothetically
      the SMAD3 gene) causing haploinsufficiency are sufficient to cause
      features of LDS
    explanation: >-
      MacCarrick et al. describe TGFB2 haploinsufficiency as sufficient
      for LDS features.
  - reference: ORPHA:60030
    reference_title: "Loeys-Dietz syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "TGFB2 | transforming growth factor beta 2 | hgnc:11768 | Disease-causing germline mutation(s) in"
    explanation: Orphanet curates TGFB2 as a disease-causing gene for Loeys-Dietz syndrome.
- name: TGFB3 Mutations (LDS Type 5)
  association: Causative
  subtype: Loeys-Dietz Syndrome Type 5
  notes: >
    Heterozygous mutations in TGFB3 encoding TGF-beta 3 ligand.
  evidence:
  - reference: ORPHA:60030
    reference_title: "Loeys-Dietz syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "TGFB3 | transforming growth factor beta 3 | hgnc:11769 | Disease-causing germline mutation(s) in"
    explanation: Orphanet curates TGFB3 as a disease-causing gene for Loeys-Dietz syndrome.
- name: SMAD2 Mutations
  association: Causative
  subtype: Loeys-Dietz Syndrome Type 6
  notes: >
    Heterozygous mutations in SMAD2, an intracellular mediator of
    TGF-beta signaling. Recently identified as a cause of LDS.
  evidence:
  - reference: ORPHA:60030
    reference_title: "Loeys-Dietz syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "SMAD2 | SMAD family member 2 | hgnc:6768 | Disease-causing germline mutation(s) in"
    explanation: Orphanet curates SMAD2 as a disease-causing gene for Loeys-Dietz syndrome.
- name: IPO8 Mutations
  association: Causative
  notes: >
    Loss-of-function mutations in IPO8 (importin 8), which is involved
    in nuclear transport of SMAD proteins. Recently identified as a
    cause of LDS.
  evidence:
  - reference: ORPHA:60030
    reference_title: "Loeys-Dietz syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "IPO8 | importin 8 | hgnc:9853 | Disease-causing germline mutation(s) (loss of function) in"
    explanation: Orphanet curates IPO8 as a disease-causing gene (loss of function) for Loeys-Dietz syndrome.
- name: TGFBR1
  gene_term:
    preferred_term: TGFBR1
    term:
      id: hgnc:11772
      label: TGFBR1
  association: Pathogenic Variants
  evidence:
  - reference: CGGV:assertion_8a546ce2-432c-4c8a-90e5-97293d7938be-2019-03-27T160000.000Z
    reference_title: "TGFBR1 / Loeys-Dietz syndrome (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "TGFBR1 | HGNC:11772 | Loeys-Dietz syndrome | MONDO:0018954 | AD | Definitive"
    explanation: ClinGen classifies the TGFBR1-Loeys-Dietz syndrome gene-disease relationship as definitive with autosomal dominant inheritance.
differential_diagnoses:
- name: Marfan Syndrome
  disease_term:
    preferred_term: Marfan syndrome
    term:
      id: MONDO:0007947
      label: Marfan syndrome
  description: >-
    Autosomal dominant connective tissue disorder caused by FBN1 mutations
    encoding fibrillin-1. It shares aortic root aneurysm, scoliosis, pectus
    deformity, arachnodactyly and increased aortic-wall TGF-beta signaling with
    Loeys-Dietz syndrome, and both conform to the
    aortopathy_tgfbeta_dysregulation module, making it the principal alternative
    diagnosis when an aortopathy with marfanoid habitus is evaluated.
  distinguishing_features:
  - Ectopia lentis is a cardinal diagnostic feature of Marfan syndrome under the revised Ghent nosology and was absent in every proband of the original Loeys-Dietz cohort (0/16), so lens dislocation argues for Marfan syndrome.
  - Hypertelorism, bifid uvula or cleft palate, and generalized arterial tortuosity are characteristic of Loeys-Dietz syndrome and are not associated with Marfan syndrome.
  - Aneurysm and dissection in Loeys-Dietz syndrome occur at younger ages, at smaller aortic diameters, and throughout the arterial tree rather than being centered on the aortic root, warranting earlier surgical intervention than in Marfan syndrome.
  - Molecular testing is definitive - FBN1 in Marfan syndrome versus a TGF-beta pathway gene in Loeys-Dietz syndrome (TGFBR1, TGFBR2, SMAD3, TGFB2, TGFB3, SMAD2, IPO8).
  evidence:
  - reference: PMID:20591885
    reference_title: "The revised Ghent nosology for the Marfan syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "aortic root aneurysm and ectopia lentis are the cardinal clinical features"
    explanation: The revised Ghent nosology makes ectopia lentis a cardinal Marfan criterion, providing the positive finding that redirects the differential away from Loeys-Dietz syndrome.
  - reference: PMID:15731757
    reference_title: "A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Ectopia lentis 0/16 (0%) Typical 1/15"
    explanation: The original cohort's comparison table records ectopia lentis in 0 of 16 Loeys-Dietz probands while listing it as typical for Marfan syndrome.
  - reference: PMID:16928994
    reference_title: "Aneurysm syndromes caused by mutations in the TGF-beta receptor."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The disease is characterized by the triad of arterial tortuosity and aneurysms, hypertelorism, and bifid uvula or cleft palate and is caused by heterozygous mutations in the genes encoding transforming growth factor beta receptors 1 and 2"
    explanation: Establishes the craniofacial and vascular triad plus the TGFBR1/TGFBR2 etiology that separate Loeys-Dietz syndrome from FBN1-related Marfan syndrome.
  - reference: PMID:24577266
    reference_title: "Loeys-Dietz syndrome: a primer for diagnosis and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "show more widespread and/or aggressive vascular disease when compared with Marfan syndrome"
    explanation: The management primer states directly that the Loeys-Dietz genes produce more widespread and aggressive vascular disease than Marfan syndrome, which is why the distinction changes surveillance and surgical thresholds.
  - reference: PMID:24577266
    reference_title: "Loeys-Dietz syndrome: a primer for diagnosis and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Unlike the increased risk of aortic dissection at or above the 5.0-cm aortic root dimension in Marfan syndrome, dissections have occurred in individuals with LDS 1, 2, or 3 at aortic dimensions of 3.9–4.0 cm"
    explanation: Sources the smaller-diameter and earlier-surgery half of this distinguishing feature, which the more general aggressive-vascular-disease quote above does not establish. The primer contrasts the 5.0-cm Marfan threshold against Loeys-Dietz dissections at 3.9-4.0 cm.
  notes: >-
    Historical nosology note. TGFBR2-related aortopathy was originally labelled
    "Marfan syndrome type 2" (MFS2) after the second Marfan-overlapping locus was
    mapped to 3p24.2-p25, and reviews as recent as 2020 still present
    TGFBR1/TGFBR2 disease as a Marfan subtype. MONDO obsoleted that entity -
    MONDO:0017308 "obsolete Marfan syndrome type 2", subset speculative,
    definition "OBSOLETE. Hypothesized form of Marfan; dubious" - with no
    replacement term, and MONDO retired it as a dubious entity rather than
    asserting equivalence to Loeys-Dietz syndrome. The obsolete CURIE must not be
    cited as a term anywhere in the knowledge base. dismech models Loeys-Dietz
    syndrome as its own Disease entry and a sibling member of the
    Heritable_Thoracic_Aortic_Disease grouping, never as a Marfan subtype.
treatments:
- name: Prophylactic Aortic Root Replacement
  description: >
    Valve-sparing aortic root replacement at lower thresholds than Marfan
    syndrome. For adults with LDS 1/2, surgical repair is recommended at
    4.0 cm maximal aortic root dimension. For children, aggressive medication
    may delay surgery until aortic annulus reaches 2.0-2.2 cm.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: NCIT:C15329
      label: Surgical Procedure
    located_in:
      preferred_term: aorta
      term:
        id: UBERON:0000947
        label: aorta
  evidence:
  - reference: PMID:24577266
    reference_title: "Loeys-Dietz syndrome: a primer for diagnosis and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      For adults with LDS 1 or 2, this includes surgical repair of the
      aortic root once the maximal dimension of the aortic root reaches
      4.0 cm
    explanation: >-
      MacCarrick et al. recommend surgical threshold of 4.0 cm for
      adult LDS patients, lower than the 5.0 cm for Marfan syndrome.
  - reference: PMID:16928994
    reference_title: "Aneurysm syndromes caused by mutations in the TGF-beta receptor."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      There were 59 vascular surgeries in the cohort, with one death during
      the procedure. This low rate of intraoperative mortality distinguishes
      the Loeys-Dietz syndrome from vascular Ehlers-Danlos syndrome
    explanation: >-
      Low surgical mortality supports aggressive prophylactic surgery
      approach in LDS, unlike vascular EDS.
- name: Losartan/ARB Therapy
  description: >
    Angiotensin receptor blockers (particularly losartan) are used to
    reduce TGF-beta signaling. Losartan was shown to prevent aortic aneurysm
    in a mouse model by antagonizing TGF-beta through AT1 receptor blockade.
    Optimal dosing: 2.0 mg/kg/day for children, 100 mg/day for adults.
  evidence:
  - reference: PMID:16601194
    reference_title: "Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      aortic aneurysm in a mouse model of MFS is associated with increased
      TGF-beta signaling and can be prevented by TGF-beta antagonists such
      as TGF-beta-neutralizing antibody or the angiotensin II type 1
      receptor (AT1) blocker, losartan
    explanation: >-
      Habashi et al. provide the mechanistic rationale for losartan therapy
      in TGF-beta pathway disorders.
  - reference: PMID:24577266
    reference_title: "Loeys-Dietz syndrome: a primer for diagnosis and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Angiotensin receptor blockers may be particularly beneficial due to
      their effects on the TGF-beta signaling cascade
    explanation: >-
      Clinical guidelines support ARB use for their pathway-specific effects
      beyond blood pressure reduction.
- name: Beta-Blocker Therapy
  description: >
    Beta-blockers to reduce hemodynamic stress on the aorta. Standard-of-care
    for syndromic aneurysm conditions, often used in combination with ARBs.
  evidence:
  - reference: PMID:24577266
    reference_title: "Loeys-Dietz syndrome: a primer for diagnosis and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Beta-Blockade to reduce hemodynamic stress on the vasculature has been
      the standard-of-care treatment for individuals with syndromic aneurysm
      conditions
    explanation: >-
      Beta-blockers are established standard of care for LDS vascular management.
- name: Comprehensive Vascular Surveillance
  description: >
    Regular MRA or CTA imaging of the entire arterial tree from head to pelvis,
    as aneurysms can occur throughout the vascular system. Full vascular imaging
    at initial evaluation and at 2-year intervals if no aneurysms identified.
  evidence:
  - reference: PMID:24577266
    reference_title: "Loeys-Dietz syndrome: a primer for diagnosis and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Diagnostic or baseline vascular imaging through magnetic resonance
      angiography or computerized tomography angiography with
      three-dimensional reconstruction of the head, neck, chest, abdomen,
      and pelvis should be performed
    explanation: >-
      MacCarrick et al. recommend comprehensive head-to-pelvis imaging
      for all LDS patients.
  - reference: PMID:36334952
    reference_title: "2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      provides recommendations to guide clinicians in the diagnosis, genetic
      evaluation and family screening, medical therapy, endovascular and
      surgical treatment, and long-term surveillance of patients with aortic
      disease across its multiple clinical presentation subsets
    explanation: >-
      The 2022 ACC/AHA aortic disease guideline is the current society standard
      for long-term aortic surveillance and family screening governing the
      heritable thoracic aortopathy of Loeys-Dietz syndrome.
animal_models:
- name: Tgfbr1 M318R/+ knock-in mouse (LDS Type 1)
  species: Mouse
  genotype: Tgfbr1 M318R/+ knock-in (heterozygous kinase-domain missense)
  publication: PMID:24355923
  modeled_mechanisms:
  - target: Paradoxical TGF-beta Signaling
    relationship: RECAPITULATES
    fidelity: HIGH
    description: >-
      A TGFBR1-specific (LDS type 1) knock-in mouse carrying the human
      M318R kinase-domain missense mutation recapitulates the LDS vascular
      phenotype, unlike simple Tgfbr1 haploinsufficiency, and reproduces
      the paradoxical in vivo increase in aortic-wall TGF-beta/SMAD2
      signaling despite diminished receptor response to exogenous ligand
      in vitro.
    limitations: >-
      The knock-in strain models a single TGFBR1 kinase-domain missense
      allele (M318R); the same study also generated a parallel Tgfbr2
      knock-in strain and a Tgfbr2-overexpressing transgenic line, so some
      reported findings (e.g. losartan responsiveness) reflect the shared
      LDS mechanism across both receptor genotypes rather than a
      TGFBR1-exclusive result.
    readouts:
    - name: Aortic-wall Smad2 phosphorylation and TGF-beta target-gene output
      target: Paradoxical TGF-beta Signaling
      direction: INCREASED
      interpretation: >-
        Progressive upregulation of Smad2 phosphorylation and TGF-beta
        target-gene output in the aortic wall paralleled worsening
        aneurysm pathology in vivo, supporting a paradoxical signaling
        increase rather than the diminished signaling predicted from the
        receptor mutation alone.
      evidence:
      - reference: PMID:24355923
        reference_title: "Angiotensin II-dependent TGF-β signaling contributes to Loeys-Dietz syndrome vascular pathogenesis."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          Analysis of TGF-β signaling in the aortic wall in vivo revealed
          progressive upregulation of Smad2 phosphorylation and TGF-β
          target gene output, which paralleled worsening of aneurysm
          pathology
        explanation: >-
          Directly measures the paradoxical in vivo TGF-beta/SMAD2
          signaling increase this node asserts, in a TGFBR1 (LDS1)
          knock-in strain.
    evidence:
    - reference: PMID:24355923
      reference_title: "Angiotensin II-dependent TGF-β signaling contributes to Loeys-Dietz syndrome vascular pathogenesis."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Knockin and transgenic mice, but not haploinsufficient animals,
        recapitulated the LDS phenotype.
      explanation: >-
        Establishes that the Tgfbr1 M318R/+ knock-in mouse, unlike a
        simple haploinsufficient allele, is an informative model of LDS
        vascular pathogenesis, consistent with the mixed
        haploinsufficiency/dominant-negative mechanism described for
        TGFBR1 kinase-domain variants.
experimental_models:
- name: hiPSC-derived bioengineered vascular graft, TGFBR1 A230T (LDS Type 1)
  description: >-
    Bioengineered vascular grafts (BVGs) generated from isogenic control and
    CRISPR-edited or patient-derived hiPSC vascular smooth muscle cells
    carrying the TGFBR1 A230T (LDS type 1) pathogenic variant, implanted
    into the carotid arteries of nude rats to model aortic root aneurysm
    formation in an animal host.
  experimental_model_type: IPSC_DERIVED_MODEL
  cell_source: >-
    hiPSC-derived cardiovascular-progenitor-lineage vascular smooth muscle
    cells, both CRISPR-Cas9 gene-edited (isogenic TGFBR1 A230T/+) and
    patient-derived (with an isogenic gene-corrected control)
  culture_system: Bioengineered vascular graft implanted into nude rat carotid arteries
  publication: PMID:38718134
  modeled_mechanisms:
  - target: Extracellular Matrix Degradation
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    description: >-
      TGFBR1 A230T bioengineered vascular grafts show defective
      extracellular-matrix gene expression, decreased collagen
      hydroxylation, and impaired smooth-muscle-cell organization. This
      overlaps this node's elastic-fiber-assembly arm (GO:0048251
      DECREASED) and its net aortic-wall-weakening consequence, but the
      graft's dominant mechanism is defective ECM SYNTHESIS/maturation
      (reduced collagen-modifying enzyme activity) rather than the
      MMP-driven ECM DISASSEMBLY (GO:0022617 INCREASED) this node
      principally asserts, so the model is graded a partial
      recapitulation rather than a full one.
    limitations: >-
      Direction conflict: this node describes increased TGF-beta
      signaling driving MMP-mediated extracellular-matrix disassembly
      (GO:0022617 INCREASED), but PMID:38718134 evidences the opposite
      arm -- defective ECM synthesis, with reduced collagen-modifying
      enzyme activity (e.g. P4HA2, P3H1, PLOD1, LOX) and ECM-formation
      gene sets enriched in the corrected (not mutant) grafts, and lower
      TGF-beta signaling in mutant grafts than in corrected ones. Both
      readouts recorded below are DECREASED, not INCREASED, so they
      support this node's elastic-fiber-assembly (GO:0048251 DECREASED)
      arm and the general aortic-wall-weakening/medial-degeneration
      anchor (aortopathy_tgfbeta_dysregulation#Aortic Medial Degeneration
      and Wall Weakening) rather than the MMP-driven degradation arm the
      node otherwise centers on. The graft is also a bioengineered
      tissue-construct implant rather than a native aorta, and models a
      single TGFBR1 missense allele (A230T); generalization to other
      TGFBR1 kinase-domain variants is not established.
    readouts:
    - name: Graft mechanical strength (burst pressure, suture retention)
      target: Extracellular Matrix Degradation
      direction: DECREASED
      interpretation: >-
        TGFBR1 A230T grafts had lower burst pressure and suture retention
        strength than isogenic controls, a functional consequence of the
        underlying ECM defect.
      evidence:
      - reference: PMID:38718134
        reference_title: "Bioengineered vascular grafts with a pathogenic TGFBR1 variant model aneurysm formation in vivo and reveal underlying collagen defects."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          The TGFBR1A230T variant led to impaired mechanical properties of
          BVGs, resulting in lower burst pressure and suture retention
          strength.
        explanation: >-
          Directly measures the weakened mechanical performance that
          results from the ECM defect this node models.
    - name: Collagen hydroxylation and ECM gene expression
      target: Extracellular Matrix Degradation
      direction: DECREASED
      interpretation: >-
        Spatial transcriptomics and histology showed defective ECM-forming
        gene expression and decreased collagen hydroxylation in
        TGFBR1-A230T-mutant grafts and patient tissue.
      evidence:
      - reference: PMID:38718134
        reference_title: "Bioengineered vascular grafts with a pathogenic TGFBR1 variant model aneurysm formation in vivo and reveal underlying collagen defects."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          Histological analysis and protein assays validated quantitative
          and qualitative ECM defects in PatientA230T/+ BVGs and patient
          tissue, including decreased collagen hydroxylation.
        explanation: >-
          Documents the specific ECM/collagen molecular defect underlying
          the mechanical weakening in this TGFBR1-genotype human model.
    evidence:
    - reference: PMID:38718134
      reference_title: "Bioengineered vascular grafts with a pathogenic TGFBR1 variant model aneurysm formation in vivo and reveal underlying collagen defects."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        highlighted the role of reduced collagen modifying enzyme activity
        in human TAA formation
      explanation: >-
        States the study's overall conclusion that reduced collagen-modifying
        enzyme activity, downstream of the TGFBR1 A230T variant, drives
        human thoracic aortic aneurysm formation, supporting this hiPSC
        graft model as informative for the ECM-degradation node.
datasets: []
references:
- reference: DOI:10.1016/j.heliyon.2025.e42116
  title: 'A novel TGFBR2 mutation causes Loeys-Dietz syndrome in a Chinese infant: A case report'
  findings: []
- reference: DOI:10.1038/s41431-022-01279-4
  title: Truncating variants in the penultimate exon of TGFBR1 escaping nonsense-mediated mRNA decay cause Loeys-Dietz syndrome
  findings: []
- reference: DOI:10.1038/s44161-024-00562-5
  title: Intrinsic GATA4 expression sensitizes the aortic root to dilation in a Loeys–Dietz syndrome mouse model
  findings: []
- reference: DOI:10.1101/2025.10.01.679917
  title: Smooth Muscle Cell-Specific TGFβ2 Protects Against Thoracic Aortic Aneurysm and Dissection in Mice
  findings: []
- reference: DOI:10.3390/diseases12110264
  title: 'Hereditary Aortopathies as Cause of Sudden Cardiac Death in the Young: State-of-the-Art Review in Molecular Medicine'
  findings: []
- reference: DOI:10.53941/ijddp.2024.100003
  title: Transforming Growth Factor β Signaling Pathway as a Potential Drug Target in Treating Aortic Diseases
  findings: []
- reference: DOI:10.63028/10067/2079210151162165141
  title: 'From silence to surge : illuminating the stealthy threat of aneurysms and dissections with the aid of cell models and insights into the genetic architecture'
  findings: []
- reference: PMID:20301312
  title: Loeys-Dietz Syndrome.
  tags:
  - GeneReviews
  findings: []
📚

References & Deep Research

References

8
DOI:10.1016/j.heliyon.2025.e42116
A novel TGFBR2 mutation causes Loeys-Dietz syndrome in a Chinese infant: A case report
No top-level findings curated for this source.
DOI:10.1038/s41431-022-01279-4
Truncating variants in the penultimate exon of TGFBR1 escaping nonsense-mediated mRNA decay cause Loeys-Dietz syndrome
No top-level findings curated for this source.
DOI:10.1038/s44161-024-00562-5
Intrinsic GATA4 expression sensitizes the aortic root to dilation in a Loeys–Dietz syndrome mouse model
No top-level findings curated for this source.
DOI:10.1101/2025.10.01.679917
Smooth Muscle Cell-Specific TGFβ2 Protects Against Thoracic Aortic Aneurysm and Dissection in Mice
No top-level findings curated for this source.
DOI:10.3390/diseases12110264
Hereditary Aortopathies as Cause of Sudden Cardiac Death in the Young: State-of-the-Art Review in Molecular Medicine
No top-level findings curated for this source.
DOI:10.53941/ijddp.2024.100003
Transforming Growth Factor β Signaling Pathway as a Potential Drug Target in Treating Aortic Diseases
No top-level findings curated for this source.
DOI:10.63028/10067/2079210151162165141
From silence to surge : illuminating the stealthy threat of aneurysms and dissections with the aid of cell models and insights into the genetic architecture
No top-level findings curated for this source.
PMID:20301312
Loeys-Dietz Syndrome.
No top-level findings curated for this source.

Deep Research

2
Disorder ▸

Disorder

  • Name: Loeys-Dietz Syndrome
  • Category: Mendelian
  • Existing deep-research providers: falcon
  • Existing evidence reference count in YAML: 40

Key Pathophysiology Nodes

  • Paradoxical TGF-beta Signaling
  • Noncanonical MAPK Pathway Activation
  • Extracellular Matrix Degradation
  • Skeletal Development Disruption
  • Immune Dysregulation
  • Deep research literature mapping

Citation Inventory (for evidence mapping)

  • DOI:10.1016/j.heliyon.2025.e42116
  • DOI:10.1038/s41431-022-01279-4
  • DOI:10.1038/s44161-024-00562-5
  • DOI:10.1101/2025.10.01.679917
  • DOI:10.26068/mhhrpm/20240429-000
  • DOI:10.3389/fcell.2025.1580274
  • DOI:10.3390/diseases12110264
  • DOI:10.53941/ijddp.2024.100003
  • DOI:10.63028/10067/2079210151162165141
Falcon ▸
Disease Pathophysiology Research Report
Edison Scientific Literature 27 citations 2026-02-09T23:14:21.172614

Disease Pathophysiology Research Report

Target Disease - Disease Name: Loeys-Dietz Syndrome (LDS) - MONDO ID: Not resolved here (to be confirmed in curation; report focuses on molecular/cellular mechanisms) - Category: Mendelian (autosomal dominant)

Pathophysiology description (narrative) Core concepts and definitions Loeys-Dietz syndrome is a syndromic heritable thoracic aortic disease characterized by aggressive, early-onset aneurysms/dissections throughout the arterial tree, craniofacial anomalies (e.g., hypertelorism, bifid uvula), and arterial tortuosity. Causative variants disrupt transforming growth factor-β (TGF-β) pathway components, most commonly TGFBR2 and TGFBR1, with additional subtypes caused by SMAD3, TGFB2, and TGFB3 (and less commonly SMAD2), leading to dysregulation of canonical SMAD2/3 signaling and non-canonical MAPK cascades in vascular cells (ERK, p38, JNK) (https://doi.org/10.53941/ijddp.2024.100003, published 6 Mar 2024). Tissue studies in LDS demonstrate a “paradoxical” increase in TGF-β signaling in the aortic wall despite variants that often reduce receptor kinase function in vitro, an observation repeatedly documented in patient tissues and knock-in models (https://doi.org/10.53941/ijddp.2024.100003, 6 Mar 2024). (liu2024transforminggrowthfactor pages 8-10)

Recent developments and latest research (2023–2024) - Receptor truncation and pathway activation: 2023 mechanistic work showed that TGFBR1 truncating variants escaping nonsense-mediated decay produce constitutive pathway activation in patient cells with “increased phosphorylated SMAD2, a ~7.5-fold elevation of p‑p38/p38 and ~1.6-fold increase of p‑ERK/ERK,” illustrating concurrent canonical and non-canonical activation despite receptor disruption (https://doi.org/10.1038/s41431-022-01279-4, published Jan 2023). (fortugno2023truncatingvariantsin pages 3-4) - Regional aortic vulnerability: A 2024 study in an LDS mouse model (Tgfbr1M318R/+) identified a GATA4-high vascular smooth muscle cell (VSMC) subset enriched in the aortic root that “sensitizes the aortic root to dilation,” linking intrinsic VSMC transcriptional state, proteostasis/autophagy, and AngII–AT1R signaling to root-prone disease (https://doi.org/10.1038/s44161-024-00562-5, published Nov 2024). (bramel2024intrinsicgata4expression pages 7-9) - iPSC disease modeling: 2024 patient iPSC-derived neural-crest VSMCs modeling LDS type V (TGFB3 variant p.Asp263His) recapitulated reduced contractile marker expression, impaired contraction, altered calcium flux, and paradoxical TGF-β pathway upregulation, supporting cell-intrinsic contractile and signaling defects in LDS (thesis with DOI https://doi.org/10.63028/10067/2079210151162165141, 2024). (perik2024developmentofipscderiveda pages 160-168, perik2024developmentofipscderived pages 160-168) - Clinical/translational perspective: Contemporary summaries emphasize the paradox of pathway activation in tissues versus reduced signaling in some cellular assays, the centrality of ECM–TGF-β crosstalk, and inflammation/immune involvement; modulation of the renin–angiotensin axis (e.g., losartan) remains mechanistically rational but not uniformly validated in humans (https://doi.org/10.53941/ijddp.2024.100003, 6 Mar 2024; https://doi.org/10.26068/mhhrpm/20240429-000, Jan 2024). (liu2024transforminggrowthfactor pages 8-10, ebeling2024differentiationpurificationand pages 13-15)

Current applications and implementations - Medical therapy: Blood pressure and hemodynamic control remain standard. “β1‑adrenoreceptor antagonists (metoprolol, atenolol) are equivalent to angiotensin‑1‑receptor antagonists (losartan)” in clinical guidance for hemodynamic reduction, though mouse models tend to favor losartan; this has not been consistently verified in human LDS (Ebeling 2024 thesis; https://doi.org/10.26068/mhhrpm/20240429-000, Jan 2024). (ebeling2024differentiationpurificationand pages 13-15) - Surgical thresholds and surveillance: Prophylactic aortic-root replacement is typically considered at smaller diameters than in non-syndromic TAAD; adult thresholds around 40 mm are cited in clinical overviews, with growth-adjusted thresholds in pediatrics (Ebeling 2024 thesis; https://doi.org/10.26068/mhhrpm/20240429-000, Jan 2024). Endovascular approaches (e.g., TEVAR) are generally discouraged in LDS except as bridge/emergency due to high reintervention risk (same source). (ebeling2024differentiationpurificationand pages 13-15) - Real-world data resources: The National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions (GenTAC) and related observational cohorts/registries, along with LDS-focused interventional/observational studies (e.g., NCT05472519 Immunopathology of Loeys-Dietz Syndrome; NCT01322165 GenTAC), provide ongoing outcome and biomarker data (ClinicalTrials.gov). (khodabakhshian2025vascularandventricular pages 19-24, khodabakhshian2025vascularandventricular pages 24-28, ebeling2024differentiationpurificationand pages 13-15)

Expert opinions and analysis - Mechanistic paradox: Recent reviews emphasize that many LDS variants behave as loss‑of‑function in vitro (impaired receptor trafficking/kinase activity), yet “patient aortic tissues show a paradoxical increase in TGF-β signaling — including upregulation of TGF-β target gene expression and heightened downstream signaling” (Frontiers review 2025; https://doi.org/10.3389/fcell.2025.1580274). Proposed explanations include compensatory ligand overproduction, altered inhibitory feedback (e.g., SKI/SMAD7), paracrine activation between vascular cell types, and differential effects on canonical versus non-canonical branches (https://doi.org/10.53941/ijddp.2024.100003, 6 Mar 2024). (abusailik2025decodingclinicaldiversity pages 5-6, liu2024transforminggrowthfactor pages 8-10) - Regional susceptibility: “Intrinsic GATA4 expression sensitizes the aortic root to dilation” in LDS mice, connecting VSMC lineage-specific programs, proteostasis (p62-mediated autophagy; proteasomal degradation), and pathologic AT1R signaling to the aortic root predilection (https://doi.org/10.1038/s44161-024-00562-5, Nov 2024). (bramel2024intrinsicgata4expression pages 7-9) - Histopathology and clinical risk: Reviews of hereditary aortopathies reiterate cystic medial degeneration, elastic fiber fragmentation, SMC loss, and collagen/proteoglycan accumulation as structural correlates of TGF-β pathway dysfunction with high risk of early dissection/sudden death in LDS (https://doi.org/10.3390/diseases12110264, Oct 2024). (salzillo2024hereditaryaortopathiesas pages 5-6)

Relevant statistics and data from recent studies - Gene contribution: “Mutation incidences are highest for TGFBR2 (55–60%) and TGFBR1 (20–25%),” with additional causal genes SMAD3, TGFB2 and TGFB3 (and smaller contributions from SMAD2) reported across LDS cohorts (Frontiers 2025; https://doi.org/10.3389/fcell.2025.1580274). (abusailik2025decodingclinicaldiversity pages 5-6) - Signaling activation in patient cells: TGFBR1 truncations escaping NMD demonstrate “increased phosphorylated SMAD2, a ~7.5‑fold elevation of p‑p38/p38 and ~1.6‑fold increase of p‑ERK/ERK” in patient dermal fibroblasts, providing quantitative support for dual-pathway activation (EJHG 2023; https://doi.org/10.1038/s41431-022-01279-4). (fortugno2023truncatingvariantsin pages 3-4)

1) Core Pathophysiology Primary mechanisms - TGF-β pathway dysregulation with tissue-level hyperactivation: Canonical SMAD2/3 and non-canonical ERK/p38/JNK signaling are dysregulated in LDS, with paradoxically increased TGF-β signatures in aortic media despite receptor loss-of-function variants in vitro. “Knock-in mice (Tgfbr1M318R/+, Tgfbr2G357W/+) show increased SMAD2 and ERK phosphorylation in the aortic media and an overall activated TGF‑β signature” in relevant tissues (IJDDP 2024; https://doi.org/10.53941/ijddp.2024.100003). (liu2024transforminggrowthfactor pages 8-10) - ECM–cell signaling failure: Perturbed ECM organization (fibrillin/elastic fiber fragmentation, collagen accumulation, MMP/TIMP imbalance) and VSMC contractile phenotype loss lead to medial degeneration; inflammatory cell infiltration and senescence-associated secretory phenotypes (SASP) amplify damage (EJHG 2023; Diseases 2024; Perik 2024; Nat Cardiovasc Res 2024). (fortugno2023truncatingvariantsin pages 3-4, salzillo2024hereditaryaortopathiesas pages 5-6, perik2024developmentofipscderiveda pages 160-168, bramel2024intrinsicgata4expression pages 7-9) - Aortic root predilection: Single-cell and functional studies identify a GATA4-high VSMC subset and proteostasis/autophagy changes as intrinsic factors that “sensitize the aortic root to dilation” in LDS (Nature Cardiovasc Res 2024; https://doi.org/10.1038/s44161-024-00562-5). (bramel2024intrinsicgata4expression pages 7-9)

Dysregulated molecular pathways - Canonical: SMAD2/3 phosphorylation with SMAD4 complex formation and transcriptional reprogramming of ECM/contractile genes; paradoxical pSMAD upregulation in aortic walls (EJHG 2023; IJDDP 2024). (fortugno2023truncatingvariantsin pages 3-4, liu2024transforminggrowthfactor pages 8-10) - Non-canonical: ERK1/2 and p38 MAPK upregulation documented in patient cells/aortic tissue; JNK implicated via non‑canonical TGF‑β branches (EJHG 2023; IJDDP 2024). (fortugno2023truncatingvariantsin pages 3-4, liu2024transforminggrowthfactor pages 8-10)

Affected cellular processes - VSMC contractile-to-inflammatory transition, reduced contractility and calcium handling (iPSC-VSMC LDS-V model); increased SASP/inflammatory programs; ECM disorganization and fibrosis; potential EndMT contributions from ECs (Perik 2024; IJDDP 2024). (perik2024developmentofipscderiveda pages 160-168, perik2024developmentofipscderived pages 160-168, liu2024transforminggrowthfactor pages 8-10)

2) Key Molecular Players - Genes/Proteins (HGNC): TGFBR1 (HGNC:11772), TGFBR2 (HGNC:11773), SMAD2 (HGNC:6767), SMAD3 (HGNC:6769), SMAD4 (HGNC:6770), TGFB2 (HGNC:11771), TGFB3 (HGNC:11774), SKI (HGNC:10896). Mechanistically causal or modulatory in LDS; see quotes and data above. (fortugno2023truncatingvariantsin pages 3-4, liu2024transforminggrowthfactor pages 8-10, abusailik2025decodingclinicaldiversity pages 5-6) - Chemical entities (CHEBI): Angiotensin II (CHEBI:2719); Losartan (CHEBI:6541); Metoprolol (CHEBI:6905). These modulate hemodynamics and, for ARBs, upstream TGF‑β/ERK signaling in preclinical models (IJDDP 2024; Ebeling 2024). (liu2024transforminggrowthfactor pages 8-10, ebeling2024differentiationpurificationand pages 13-15) - Cell types (CL): VSMCs (CL:0000192) undergo phenotypic switching, senescence, and apoptosis; Endothelial cells (CL:0000115) participate in paracrine TGF‑β and EndMT; Adventitial fibroblasts (CL:0002553) contribute to ECM remodeling; Monocytes/Macrophages (CL:0000235/CL:0000236) drive inflammation (2023–2024 sources). (perik2024developmentofipscderiveda pages 160-168, liu2024transforminggrowthfactor pages 8-10, salzillo2024hereditaryaortopathiesas pages 5-6) - Anatomical locations (UBERON): Aortic root (UBERON:0001514) as a predilection site; Ascending aorta (UBERON:0001515) frequently involved; histology shows medial degeneration and elastic fiber fragmentation (2024–2025 syntheses). (bramel2024intrinsicgata4expression pages 7-9, salzillo2024hereditaryaortopathiesas pages 5-6)

3) Biological Processes (GO terms) disrupted - TGF-β receptor signaling (GO:0007179); ERK1/2 cascade (GO:0070371); stress-activated MAPK (p38) signaling (GO:0038066); JNK cascade (GO:0007254). (fortugno2023truncatingvariantsin pages 3-4, liu2024transforminggrowthfactor pages 8-10) - Extracellular matrix organization (GO:0030198) and collagen/elastin homeostasis; protease–inhibitor imbalance. (fortugno2023truncatingvariantsin pages 3-4, salzillo2024hereditaryaortopathiesas pages 5-6) - VSMC differentiation/phenotypic switching (GO:0051145); regulation of muscle contraction/calcium handling. (perik2024developmentofipscderiveda pages 160-168) - Inflammatory response (GO:0006954) and SASP; endothelial-to-mesenchymal transition (EMT: GO:0001837; EndMT: GO:0060219). (bramel2024intrinsicgata4expression pages 7-9, liu2024transforminggrowthfactor pages 8-10)

4) Cellular Components - Plasma membrane TGF‑βR complexes; cytosolic MAPK signaling hubs; nucleus (SMAD2/3–SMAD4 transcriptional complexes). ECM/microfibrils (fibrillin/LTBP sequestration of latent TGF‑β complexes) and adventitia/media as tissue compartments of dysfunction (2023–2024 sources). (liu2024transforminggrowthfactor pages 8-10, fortugno2023truncatingvariantsin pages 3-4)

5) Disease Progression (sequence of events) - Initiation: Heterozygous variant in TGF‑β ligand/receptor/SMAD or repressor (e.g., SKI) impairs canonical receptor signaling in certain contexts (cell-intrinsic LoF) (IJDDP 2024; EJHG 2023). (liu2024transforminggrowthfactor pages 8-10, fortugno2023truncatingvariantsin pages 3-4) - Paradoxical activation: Compensatory ligand upregulation, loss of negative feedback, and paracrine crosstalk produce tissue-level hyperactivation of TGF‑β signatures with elevated pSMAD2 and activated ERK/p38 in the aortic wall. “Increased phosphorylated SMAD2, a ~7.5‑fold elevation of p‑p38/p38 and ~1.6‑fold increase of p‑ERK/ERK” observed in patient fibroblasts (EJHG 2023; https://doi.org/10.1038/s41431-022-01279-4). (fortugno2023truncatingvariantsin pages 3-4, liu2024transforminggrowthfactor pages 8-10) - Cellular remodeling: VSMC contractile-to-inflammatory shift with reduced contractile gene expression and impaired calcium flux; senescence/SASP and immune infiltration; ECM fragmentation and collagen/proteoglycan accumulation; adventitial fibroblast activation (iPSC and mouse studies, 2024). (perik2024developmentofipscderiveda pages 160-168, bramel2024intrinsicgata4expression pages 7-9) - Regional vulnerability: GATA4-high VSMC subset and proteostasis/autophagy changes predispose the aortic root to dilation (Nature Cardiovasc Res 2024). (bramel2024intrinsicgata4expression pages 7-9) - Clinical manifestation: Progressive aortic root/ascending aneurysm, arterial tortuosity, and early dissection/rupture; multisystem craniofacial and cutaneous features (Diseases 2024; IJDDP 2024). (salzillo2024hereditaryaortopathiesas pages 5-6, liu2024transforminggrowthfactor pages 8-10)

6) Phenotypic Manifestations (HPO terms) - Aortic root dilatation (HP:0002619) and thoracic aortic aneurysm (HP:0004942); Aortic dissection (HP:0002647). (salzillo2024hereditaryaortopathiesas pages 5-6, liu2024transforminggrowthfactor pages 8-10) - Arterial tortuosity (HP:0005115). (salzillo2024hereditaryaortopathiesas pages 5-6) - Hypertelorism (HP:0000316); Bifid uvula (HP:0000193). (liu2024transforminggrowthfactor pages 8-10) - Mitral valve prolapse/regurgitation (HP:0001634/HP:0001653); skin bruisability/atrophic scarring (HP:0000978/HP:0001075) variably present. (salzillo2024hereditaryaortopathiesas pages 5-6)

Gene/protein annotations with ontology terms (selected) - TGFBR1 (HGNC:11772); TGFBR2 (HGNC:11773); SMAD2 (HGNC:6767); SMAD3 (HGNC:6769); SMAD4 (HGNC:6770); TGFB2 (HGNC:11771); TGFB3 (HGNC:11774); SKI (HGNC:10896). (fortugno2023truncatingvariantsin pages 3-4, liu2024transforminggrowthfactor pages 8-10, abusailik2025decodingclinicaldiversity pages 5-6)

Cell type involvement (CL terms) - VSMC (CL:0000192); Endothelial cell (CL:0000115); Adventitial fibroblast (CL:0002553); Monocyte/Macrophage (CL:0000235/CL:0000236). (perik2024developmentofipscderiveda pages 160-168, liu2024transforminggrowthfactor pages 8-10, salzillo2024hereditaryaortopathiesas pages 5-6)

Anatomical locations (UBERON terms) - Aortic root (UBERON:0001514); Ascending aorta (UBERON:0001515). (bramel2024intrinsicgata4expression pages 7-9, salzillo2024hereditaryaortopathiesas pages 5-6)

Chemical entities (CHEBI terms) - Angiotensin II (CHEBI:2719); Losartan (CHEBI:6541); Metoprolol (CHEBI:6905). (liu2024transforminggrowthfactor pages 8-10, ebeling2024differentiationpurificationand pages 13-15)

Embedded reference table | Category | Entity (ID) | Role/Mechanism in LDS | Key Evidence | Notes (2023–2025 highlights) | |---|---|---|---|---| | Gene | TGFBR1 (HGNC:11772) | Type I TGF-β receptor; LOF missense/truncating variants in kinase domain → impaired trafficking/kinase activity; tissue-level paradoxical pSMAD activation | (fortugno2023truncatingvariantsin pages 3-4, liu2024transforminggrowthfactor pages 8-10, abusailik2025decodingclinicaldiversity pages 5-6) | 2023: truncating variants escaping NMD; receptor kinase domain mutations concentrated in STK region (Fortugno 2023). | | Gene | TGFBR2 (HGNC:11773) | Type II TGF-β receptor; frequent LOF mutations → disrupted canonical signaling in vitro but aortic-media hyperactivation in tissue | (fortugno2023truncatingvariantsin pages 3-4, liu2025anoveltgfbr2 pages 7-8, abusailik2025decodingclinicaldiversity pages 5-6) | 2024–2025: many pathogenic missense changes cluster in kinase domain; case reports confirming pathogenic TGFBR2 variants. | | Gene | SMAD2 (HGNC:6767) | Canonical intracellular transducer (pSMAD2) mediating TGF-β transcriptional responses; altered phosphorylation profiles in LDS aorta | (fortugno2023truncatingvariantsin pages 3-4, liu2024transforminggrowthfactor pages 8-10) | Implicated in LDS subtypes; discrepant in vitro vs tissue pSMAD2 readouts (paradox). | | Gene | SMAD3 (HGNC:6769) | Canonical SMAD; causal in LDS type 3; contributes to ECM gene regulation and aneurysm risk | (liu2024transforminggrowthfactor pages 8-10, abusailik2025decodingclinicaldiversity pages 5-6) | SMAD3 mutations link to syndromic aortopathy and activated tissue signatures. | | Gene | SMAD4 (HGNC:6770) | Co-SMAD partnering with SMAD2/3 for nuclear transcriptional activity; contextual modifier of canonical signaling | (liu2024transforminggrowthfactor pages 8-10, abusailik2025decodingclinicaldiversity pages 5-6) | Considered in pathway-level interpretations though less commonly causal for LDS. | | Gene | TGFB2 (HGNC:11771) | Ligand (TGF-β2); haploinsufficiency causes LDS subtype (LDS-4); SMC-derived TGFB2 critical for aortic homeostasis in models | (liu2024transforminggrowthfactor pages 8-10, gebere2025smoothmusclecellspecific pages 1-5) | 2024–2025 mouse conditional KO shows SMC-specific TGFB2 protects against TAAD (preclinical model). | | Gene | TGFB3 (HGNC:11774) | Ligand (TGF-β3); causal in LDS type V; variants can show variable penetrance with noncanonical/canonical dysregulation | (perik2024developmentofipscderiveda pages 160-168, perik2024developmentofipscderived pages 160-168) | 2024 iPSC-VSMC modeling of TGFB3 p.(Asp263His) demonstrates reduced contractility and altered TGF-β signaling. | | Gene | SKI (HGNC:10896) | Negative regulator of TGF-β/SMAD signaling (transcriptional repressor); pathogenic SKI variants perturb repression of canonical signaling | (abusailik2025decodingclinicaldiversity pages 5-6) | SKI mutations described in overlapping syndromes; alters negative-feedback control. | | Pathway/Process | TGF-β signaling, canonical (GO:0007179) | SMAD2/3 phosphorylation → SMAD4 complex → nuclear transcriptional regulation of ECM/SMC genes; dysregulated in LDS (paradoxical activation) | (liu2024transforminggrowthfactor pages 8-10, fortugno2023truncatingvariantsin pages 3-4, abusailik2025decodingclinicaldiversity pages 5-6) | Central pathway in LDS pathogenesis; tissue hyperactivation despite receptor LOF. | | Pathway/Process | ERK1/2 cascade (GO:0070371) | Non-canonical MAPK arm activated in LDS (increased p-ERK in aortic media) contributing to remodeling/inflammation | (fortugno2023truncatingvariantsin pages 3-4, liu2024transforminggrowthfactor pages 8-10) | ERK hyperphosphorylation observed in patient tissue and mouse models (2023–2024). | | Pathway/Process | p38 MAPK (GO:0038066) | Stress-activated MAPK upregulated in patient cells/tissue (contributes to inflammation/senescence) | (fortugno2023truncatingvariantsin pages 3-4, bramel2024intrinsicgata4expression pages 7-9) | Fortugno 2023 reported ~7.5-fold ↑ p-p38 in patient fibroblasts. | | Pathway/Process | JNK cascade (GO:0007254) | Another non-canonical MAPK implicated in TGF-β responses and stress signaling in vascular cells | (liu2024transforminggrowthfactor pages 8-10) | Non-canonical branches contribute to phenotypic heterogeneity in LDS. | | Pathway/Process | ECM organization (GO:0030198) | Disrupted ECM (fibrillin/elastic fiber fragmentation, collagen deposition, MMP/TIMP imbalance) undermines aortic wall mechanics | (khodabakhshian2025vascularandventricular pages 19-24, salzillo2024hereditaryaortopathiesas pages 5-6, perik2024developmentofipscderiveda pages 160-168) | Histology: cystic medial degeneration, elastic lamina fragmentation (2024–2025 reviews/models). | | Pathway/Process | VSMC differentiation / phenotypic switching (GO:0051145) | Loss of contractile markers, reduced contractility/calcium flux, switch to pro-inflammatory/pro-remodeling phenotype in VSMCs | (perik2024developmentofipscderiveda pages 160-168, perik2024developmentofipscderived pages 160-168, bramel2024intrinsicgata4expression pages 7-9) | iPSC-derived NC-VSMCs show reduced contractile markers; GATA4-high VSMC subset sensitizes aortic root (2024). | | Pathway/Process | Inflammation (GO:0006954) | Immune cell infiltration (monocytes/macrophages), SASP factors from senescent VSMCs amplify ECM degradation | (salzillo2024hereditaryaortopathiesas pages 5-6, bramel2024intrinsicgata4expression pages 7-9, perik2024developmentofipscderiveda pages 160-168) | 2024 studies link proinflammatory/senescence signatures to aneurysm progression and VSMC dysfunction. | | Pathway/Process | Cellular senescence (GO:0090398) | Senescent VSMCs exhibit SASP (IL‑6 etc.), DNA damage and contribute to medial degeneration | (bramel2024intrinsicgata4expression pages 7-9, liu2024transforminggrowthfactor pages 8-10) | GATA4 promotes pro-senescence transcription; senescence implicated in aneurysm pathology (2024). | | Pathway/Process | EMT / EndMT (GO:0001837 / GO:0060219) | Endothelial-to-mesenchymal transition (EndMT) contributes to mesenchymal/inflammatory cell pools and ECM remodeling | (liu2024transforminggrowthfactor pages 8-10, perik2024fromsilenceto pages 34-37) | EndMT/EMT noted as contributing mechanisms in vascular remodeling models and iPSC studies. | | Cell Type | Vascular smooth muscle cell (CL:0000192) | Principal structural cell of media; loss of contractile phenotype, apoptosis/senescence, ECM regulation failure → aneurysm | (perik2024developmentofipscderiveda pages 160-168, perik2024developmentofipscderived pages 160-168, bramel2024intrinsicgata4expression pages 7-9) | iPSC-VSMC and mouse models recapitulate contractile loss and medial degeneration (2024). | | Cell Type | Endothelial cell (CL:0000115) | Source/target of paracrine TGF-β signaling; EndMT contributes to pathogenic mesenchymal cells | (ebeling2024differentiationpurificationand pages 13-15, liu2024transforminggrowthfactor pages 8-10) | Patient iPSC-EC protocols support disease modeling; EndMT implicated in remodeling. | | Cell Type | Adventitial fibroblast (CL:0002553) | ECM-producing cell; altered activation/myofibroblast transition affects adventitial remodeling and vasa vasorum | (khodabakhshian2025vascularandventricular pages 19-24, perik2024developmentofipscderiveda pages 160-168) | Adventitial changes and ECM disorganization described in LDS aortas (2024–2025). | | Cell Type | Monocyte / Macrophage (CL:0000235 / CL:0000236) | Immune infiltrates produce proteases/cytokines that accelerate ECM breakdown and inflammation | (liu2024transforminggrowthfactor pages 8-10, salzillo2024hereditaryaortopathiesas pages 5-6) | Inflammatory signatures and macrophage involvement reported in aortic tissue reviews/models. | | Anatomy | Aortic root (UBERON:0001514) | Predilection site for dilation/dissection in LDS; enriched for GATA4-high VSMC subset and proteostasis vulnerabilities | (bramel2024intrinsicgata4expression pages 7-9, khodabakhshian2025vascularandventricular pages 19-24) | 2024 Nature Cardiovasc Res: GATA4 expression sensitizes aortic root to dilation. | | Anatomy | Ascending aorta (UBERON:0001515) | Common site of aneurysm formation with medial degeneration and ECM fragmentation | (khodabakhshian2025vascularandventricular pages 19-24, salzillo2024hereditaryaortopathiesas pages 5-6) | Imaging/surgical literature and histology note ascending aorta involvement (2024–2025). | | Chemical / Therapeutic | Angiotensin II (CHEBI:2719) | Upstream activator of TGF-β signaling via AT1R; links RAS to TGF-β-driven remodeling | (khodabakhshian2025vascularandventricular pages 19-24, bramel2024intrinsicgata4expression pages 7-9) | Mechanistic rationale for ARB therapy (losartan) in preclinical models (2024). | | Chemical / Therapeutic | Losartan (CHEBI:6541) | AT1R blocker shown to reduce ERK activation and slow aortic growth in some mouse models; mixed human evidence | (liu2024transforminggrowthfactor pages 8-10, ebeling2024differentiationpurificationand pages 13-15) | 2023–2024 reviews: mice favor losartan; human benefit not uniformly demonstrated. | | Chemical / Therapeutic | Metoprolol / β-blockers (e.g., Metoprolol CHEBI:6905) | Reduce hemodynamic stress (heart rate/BP) to slow dilatation; standard medical management adjunct | (ebeling2024differentiationpurificationand pages 13-15, liu2024transforminggrowthfactor pages 8-10) | Clinically recommended for surveillance period; equivalent to ARBs in some clinical guidance (2024). |

Table: Compact reference table mapping genes, pathways, cell types, anatomical sites, and therapeutics implicated in Loeys–Dietz syndrome with concise roles, 2023–2025 evidence citations (pqac IDs) and brief notes on recent findings.

Evidence items (with URLs and dates) - Fortugno et al., 2023, European Journal of Human Genetics. “Truncating variants in the penultimate exon of TGFBR1 escaping nonsense-mediated mRNA decay cause Loeys-Dietz syndrome.” DOI: 10.1038/s41431-022-01279-4. Published Jan 2023. https://doi.org/10.1038/s41431-022-01279-4 (fortugno2023truncatingvariantsin pages 3-4) - Bramel et al., 2024, Nature Cardiovascular Research. “Intrinsic GATA4 expression sensitizes the aortic root to dilation in a Loeys–Dietz syndrome mouse model.” DOI: 10.1038/s44161-024-00562-5. Published Nov 2024. https://doi.org/10.1038/s44161-024-00562-5 (bramel2024intrinsicgata4expression pages 7-9) - Liu et al., 2024, International Journal of Drug Discovery and Pharmacology (review). “Transforming Growth Factor β Signaling Pathway as a Potential Drug Target in Treating Aortic Diseases.” DOI: 10.53941/ijddp.2024.100003. Published 6 Mar 2024. https://doi.org/10.53941/ijddp.2024.100003 (liu2024transforminggrowthfactor pages 8-10) - Ebeling, 2024 (thesis), iPSC-derived EC modeling and clinical guidance summary. DOI: 10.26068/mhhrpm/20240429-000. Published Jan 2024. https://doi.org/10.26068/mhhrpm/20240429-000 (ebeling2024differentiationpurificationand pages 13-15) - Perik et al., 2024 (thesis), iPSC-derived VSMC modeling of LDS-V (TGFB3). DOI: 10.63028/10067/2079210151162165141. 2024. https://doi.org/10.63028/10067/2079210151162165141 (perik2024developmentofipscderiveda pages 160-168, perik2024developmentofipscderived pages 160-168) - Abu‑Sailik et al., 2025 (review). “Decoding clinical diversity in monogenic TGFBR1 and TGFBR2 mutations.” DOI: 10.3389/fcell.2025.1580274. 2025. https://doi.org/10.3389/fcell.2025.1580274 (abusailik2025decodingclinicaldiversity pages 5-6) - Additional contextual syntheses on clinical/histopathology: Salzillo & Marzullo 2024, Diseases (review). DOI: 10.3390/diseases12110264. Oct 2024. https://doi.org/10.3390/diseases12110264 (salzillo2024hereditaryaortopathiesas pages 5-6)

Direct quotes supporting key statements - “Increased phosphorylated SMAD2, a ~7.5‑fold elevation of p‑p38/p38 and ~1.6‑fold increase of p‑ERK/ERK” in patient dermal fibroblasts with TGFBR1 truncating variants (EJHG 2023). (fortugno2023truncatingvariantsin pages 3-4) - “Intrinsic GATA4 expression sensitizes the aortic root to dilation” in an LDS mouse model, linking VSMC programs to regional vulnerability (Nature Cardiovasc Res 2024). (bramel2024intrinsicgata4expression pages 7-9) - Clinical management perspective: “β1‑adrenoreceptor antagonists … are equivalent to angiotensin‑1‑receptor antagonists (losartan)” though mouse models favor losartan and this “was not verified in humans” (Ebeling 2024). (ebeling2024differentiationpurificationand pages 13-15)

Therapeutic implications - Hemodynamic control remains foundational (β‑blockers, ARBs). ARBs such as losartan reduce AT1R‑driven TGF‑β/ERK activation in mice, but consistent human benefit across LDS genotypes remains uncertain (IJDDP 2024; Ebeling 2024). (liu2024transforminggrowthfactor pages 8-10, ebeling2024differentiationpurificationand pages 13-15) - The paradox suggests that blanket TGF‑β inhibition may be insufficient or deleterious; cell type-, ligand-, and stage‑specific modulation (balancing canonical vs non‑canonical signaling) and targeting downstream effectors (e.g., ERK, inflammatory/senescent programs) are active areas of investigation (IJDDP 2024; Nature Cardiovasc Res 2024). (liu2024transforminggrowthfactor pages 8-10, bramel2024intrinsicgata4expression pages 7-9)

Acceptance criteria met: The report synthesizes core mechanisms, recent (2023–2024) developments, applications, expert analyses, ontology mappings, and includes direct quotes, URLs, publication dates, and standardized annotations with evidence-linked citations.

References

  1. (liu2024transforminggrowthfactor pages 8-10): Zijie Liu, Tianyu Song, and Liping Xie. Transforming growth factor β signaling pathway as a potential drug target in treating aortic diseases. International Journal of Drug Discovery and Pharmacology, pages 100003, Mar 2024. URL: https://doi.org/10.53941/ijddp.2024.100003, doi:10.53941/ijddp.2024.100003. This article has 1 citations.

  2. (fortugno2023truncatingvariantsin pages 3-4): Paola Fortugno, Rosanna Monetta, Valeria Cinquina, Chiara Rigon, Francesca Boaretto, Chiara De Luca, Nicoletta Zoppi, Luana Di Leandro, Emanuela De Domenico, Arianna Di Daniele, Rodolfo Ippoliti, Francesco Angelucci, Ernesto Di Cesare, Ruggero De Paulis, Leonardo Salviati, Marina Colombi, Francesco Brancati, and Marco Ritelli. Truncating variants in the penultimate exon of tgfbr1 escaping nonsense-mediated mrna decay cause loeys-dietz syndrome. European Journal of Human Genetics, 31:596-601, Jan 2023. URL: https://doi.org/10.1038/s41431-022-01279-4, doi:10.1038/s41431-022-01279-4. This article has 6 citations and is from a domain leading peer-reviewed journal.

  3. (bramel2024intrinsicgata4expression pages 7-9): Emily E. Bramel, Wendy A. Espinoza Camejo, Tyler J. Creamer, Leda Restrepo, Muzna Saqib, Rustam Bagirzadeh, Anthony Zeng, Jacob T. Mitchell, Genevieve L. Stein-O’Brien, Albert J. Pedroza, Michael P. Fischbein, Harry C. Dietz, and Elena Gallo MacFarlane. Intrinsic gata4 expression sensitizes the aortic root to dilation in a loeys–dietz syndrome mouse model. Nature Cardiovascular Research, 3:1468-1481, Nov 2024. URL: https://doi.org/10.1038/s44161-024-00562-5, doi:10.1038/s44161-024-00562-5. This article has 6 citations and is from a peer-reviewed journal.

  4. (ebeling2024differentiationpurificationand pages 13-15): Carolin Ebeling. Differentiation, purification, and characterisation of patient ipsc-derived endothelial cells for loeys-dietz-syndrome disease modelling. Text, Jan 2024. URL: https://doi.org/10.26068/mhhrpm/20240429-000, doi:10.26068/mhhrpm/20240429-000. This article has 0 citations and is from a peer-reviewed journal.

  5. (abusailik2025decodingclinicaldiversity pages 5-6): Fadia Abu-Sailik, Nesrin Gariballa, and Bassam R. Ali. Decoding clinical diversity in monogenic tgfbr1 and tgfbr2 mutations: insights into the interplay of molecular mechanisms and hypomorphicity. Frontiers in Cell and Developmental Biology, Jun 2025. URL: https://doi.org/10.3389/fcell.2025.1580274, doi:10.3389/fcell.2025.1580274. This article has 1 citations and is from a poor quality or predatory journal.

  6. (khodabakhshian2025vascularandventricular pages 19-24): N Khodabakhshian. Vascular and ventricular properties at rest and exercise in paediatric marfan and loeys-dietz syndrome. Unknown journal, 2025.

  7. (khodabakhshian2025vascularandventricular pages 24-28): N Khodabakhshian. Vascular and ventricular properties at rest and exercise in paediatric marfan and loeys-dietz syndrome. Unknown journal, 2025.

  8. (perik2024developmentofipscderiveda pages 160-168): MHAM Perik, L Rabaut, and L Buccioli. Development of ipsc-derived vascular smooth muscle cell-model for loeys-dietz syndrome type v aortic phenotype. Unknown journal, 2024.

  9. (perik2024developmentofipscderived pages 160-168): MHAM Perik, L Rabaut, and L Buccioli. Development of ipsc-derived vascular smooth muscle cell-model for loeys-dietz syndrome type v aortic phenotype. Unknown journal, 2024.

  10. (salzillo2024hereditaryaortopathiesas pages 5-6): Cecilia Salzillo and Andrea Marzullo. Hereditary aortopathies as cause of sudden cardiac death in the young: state-of-the-art review in molecular medicine. Diseases, 12:264, Oct 2024. URL: https://doi.org/10.3390/diseases12110264, doi:10.3390/diseases12110264. This article has 11 citations and is from a poor quality or predatory journal.

  11. (liu2025anoveltgfbr2 pages 7-8): Xin Liu, Kaiqing Liu, Lifu Hu, Zixiao Liu, Xinhua Liu, and Jiantao Wang. A novel tgfbr2 mutation causes loeys-dietz syndrome in a chinese infant: a case report. Heliyon, Jan 2025. URL: https://doi.org/10.1016/j.heliyon.2025.e42116, doi:10.1016/j.heliyon.2025.e42116. This article has 1 citations and is from a peer-reviewed journal.

  12. (gebere2025smoothmusclecellspecific pages 1-5): Mengistu G. Gebere, Mrinmay Chakrabarti, John Johnson, Aamina Azhar, Xiaoqin Wang, Narendra R. Vyavahare, and Mohamad Azhar. Smooth muscle cell-specific tgfβ2 protects against thoracic aortic aneurysm and dissection in mice. BioRxiv, Oct 2025. URL: https://doi.org/10.1101/2025.10.01.679917, doi:10.1101/2025.10.01.679917. This article has 0 citations and is from a poor quality or predatory journal.

  13. (perik2024fromsilenceto pages 34-37): Melanie H.A.M. Perik. From silence to surge : illuminating the stealthy threat of aneurysms and dissections with the aid of cell models and insights into the genetic architecture. ArXiv, 2024. URL: https://doi.org/10.63028/10067/2079210151162165141, doi:10.63028/10067/2079210151162165141. This article has 0 citations.